{"gene":"LRRK2","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2004,"finding":"LRRK2 (dardarin) was identified as a novel gene containing missense mutations segregating with PARK8-linked Parkinson's disease, establishing it as the causal gene for this familial PD locus.","method":"Positional cloning and candidate gene sequencing in five PD families","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1 — original gene discovery, independently replicated by a concurrent study","pmids":["15541308"],"is_preprint":false},{"year":2004,"finding":"LRRK2 encodes a large multifunctional protein belonging to the ROCO family, containing a MAPKKK-class protein kinase domain and a Ras-of-complex (Roc) GTPase domain, with six disease-segregating mutations identified including missense and splice-site variants; post-mortem analysis revealed strikingly diverse neuropathologies (Lewy body PD, diffuse Lewy body disease, nigral degeneration, PSP-like pathology) among mutation carriers.","method":"High-resolution recombination mapping, candidate gene sequencing, post-mortem neuropathology in 46 families","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1 — original domain architecture characterization with genetic and pathological validation","pmids":["15541309"],"is_preprint":false},{"year":2005,"finding":"PD-associated LRRK2 mutations (G2019S and R1441C) increase kinase activity in vitro, as measured by autophosphorylation and phosphorylation of a generic substrate, without altering protein levels or localization, supporting a gain-of-function mechanism.","method":"In vitro kinase assays with full-length recombinant LRRK2; subcellular fractionation showing mitochondrial outer membrane association","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay, independently replicated across multiple labs","pmids":["16269541"],"is_preprint":false},{"year":2006,"finding":"Kinase activity is required for the toxic effects of mutant LRRK2: a kinase-dead version of LRRK2 blocks inclusion body formation and strongly delays neuronal cell death caused by pathogenic mutations; LRRK2 protein is expressed in human midbrain neurons and C-terminal epitopes are found in some Lewy bodies.","method":"Kinase-dead mutagenesis; neuronal cell death assays; immunocytochemistry in human brain tissue","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 1 — active-site mutagenesis with cellular phenotypic readout, replicated","pmids":["16750377"],"is_preprint":false},{"year":2006,"finding":"LRRK2 kinase activity is regulated by GTP via the intrinsic GTPase Roc domain; reducing kinase activity of mutant LRRK2 correspondingly reduces neuronal toxicity, establishing that both kinase and GTPase activities are required for neurotoxicity.","method":"GTP-binding assays; kinase-dead and GTPase-dead mutagenesis; neuronal toxicity assays","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 1 — reconstituted enzymatic assays with mutagenesis and functional toxicity readout","pmids":["16980962"],"is_preprint":false},{"year":2006,"finding":"PD-associated LRRK2 mutations display disinhibited kinase activity and induce progressive reduction in neurite length and branching in primary neurons and in intact rodent CNS; LRRK2 deficiency leads to increased neurite length and branching; mutant LRRK2 neurons harbor phospho-tau-positive lysosomal inclusions and undergo apoptosis.","method":"Primary neuronal cultures; in vivo rodent CNS expression; kinase activity assays; immunofluorescence","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — loss- and gain-of-function with defined cellular phenotype, replicated","pmids":["17114044"],"is_preprint":false},{"year":2007,"finding":"Seven of ten familial LRRK2 mutations result in increased kinase activity; LRRK2 kinase activity requires GTPase activity, whereas GTPase activity functions independently of kinase activity; both activities are required for neurotoxicity and potentiation of peroxide-induced cell death.","method":"In vitro kinase assays; GTPase activity assays; mutagenesis of conserved residues; neuronal toxicity assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 — reconstituted enzymatic assays with systematic mutagenesis, replicated","pmids":["17200152"],"is_preprint":false},{"year":2007,"finding":"Purified brain LRRK2 possesses both kinase and GTPase activity (GTP binding and hydrolysis); PD mutations R1441C/G in the GTPase domain cause reduced GTP hydrolysis activity; brain LRRK2 is associated with elevated kinase activity compared to lung or cell-culture LRRK2.","method":"Purification of epitope-tagged LRRK2 from transgenic mouse brain; GTP binding and hydrolysis assays; kinase assays","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 — biochemical assay with purified protein from physiological source","pmids":["17623048"],"is_preprint":false},{"year":2007,"finding":"C. elegans LRK-1 (LRRK2 ortholog) is localized in the Golgi apparatus and is required for polarized sorting of synaptic vesicle (SV) proteins to axons by excluding SV proteins from the dendrite-specific AP-1/UNC-101 transport machinery; loss of lrk-1 results in SV proteins localizing to both presynaptic and dendritic endings.","method":"C. elegans genetics; deletion mutants; live imaging; epistasis with AP-1 mu1 adaptor UNC-101 and kinesin UNC-104","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in model organism with defined subcellular localization and transport phenotype","pmids":["17346966"],"is_preprint":false},{"year":2008,"finding":"Expression of wild-type or G2019S-LRRK2 in Drosophila causes retinal degeneration and adult-onset selective loss of dopaminergic neurons with locomotor dysfunction; G2019S causes more severe parkinsonism-like phenotype than equivalent wild-type LRRK2; L-DOPA improves locomotor impairment but does not prevent dopaminergic neuron loss.","method":"GAL4/UAS transgenic Drosophila; dopaminergic neuron counting; locomotor assays; pharmacological rescue","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function in vivo model with multiple phenotypic readouts","pmids":["18258746"],"is_preprint":false},{"year":2008,"finding":"Loss of LRRK (Drosophila LRRK2 ortholog) causes severely impaired locomotor activity and degeneration/shrinkage of dopaminergic neurons (reduced tyrosine hydroxylase immunostaining), demonstrating that LRRK2 is critical for dopaminergic neuron integrity in vivo.","method":"Drosophila loss-of-function mutants; locomotor assays; tyrosine hydroxylase immunostaining","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with defined neuronal phenotype in vivo","pmids":["17498648"],"is_preprint":false},{"year":2009,"finding":"LRRK2 kinase activity resides with dimeric LRRK2 rather than monomeric or high-molecular-weight oligomeric forms; disruption of GTPase or kinase activity enhances oligomer formation and prevents dimer formation; pathogenic mutations that increase kinase activity significantly increase the proportion of dimer structures; kinase inhibition by staurosporine ablates LRRK2 dimers.","method":"Size-exclusion chromatography/fractionation; kinase activity assays of separated fractions; kinase inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — biochemical fractionation with direct kinase activity measurement","pmids":["19826009"],"is_preprint":false},{"year":2010,"finding":"LRRK2 binds to MAP kinase kinases MKK3, MKK6, and MKK7, and also binds to JNK-interacting proteins JIP1, JIP2, JIP3, and JIP4; LRRK2 association correlates with increased total JIP1, JIP3, JIP4, oligomeric JIP and ubiquitinated JIP levels, implicating LRRK2 in regulation of the stress kinase cascade.","method":"Co-immunoprecipitation; immunoblot analysis of JIP levels","journal":"Neuro-degenerative diseases","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP binding data, single lab, no direct kinase assay of the interaction","pmids":["20173330"],"is_preprint":false},{"year":2012,"finding":"ArfGAP1 is the first identified GTPase activating protein (GAP) for LRRK2; ArfGAP1 binds LRRK2 predominantly via the WD40 and kinase domains, increases LRRK2 GTPase activity, and regulates LRRK2 toxicity in vitro and in Drosophila; reciprocally, LRRK2 phosphorylates ArfGAP1 and inhibits its GAP activity, while ArfGAP1 reduces LRRK2 autophosphorylation and kinase activity.","method":"Co-IP; in vitro GTPase activity assays; in vitro kinase assays; Drosophila toxicity assays; shRNA knockdown","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biochemical assays plus in vivo Drosophila validation","pmids":["22423108"],"is_preprint":false},{"year":2013,"finding":"LRRK2 is degraded in lysosomes by chaperone-mediated autophagy (CMA); the pathogenic G2019S mutant is poorly degraded by CMA; both wild-type and pathogenic mutant LRRK2 interfere with the CMA translocation complex in the presence of other CMA substrates, resulting in defective CMA and self-perpetuating inhibition; this was observed in neuronal cultures, LRRK2 transgenic mouse brain, iPSC-derived dopaminergic neurons, and PD patient brains.","method":"Lysosomal binding assays; CMA flux measurements; LRRK2 transgenic mice; iPSC-derived DA neurons; human PD brain tissue analysis","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal models and methods, replicated in human tissue","pmids":["23455607"],"is_preprint":false},{"year":2013,"finding":"RAB7L1 (encoded at the PARK16 locus) interacts with LRRK2 and modifies intraneuronal protein sorting; deficiency of RAB7L1 in rodent neurons or its Drosophila ortholog recapitulates degeneration seen with familial LRRK2 mutations; RAB7L1 overexpression rescues LRRK2 mutant phenotypes; PD-associated defects in RAB7L1 or LRRK2 lead to endolysosomal and Golgi sorting defects and deficiency of the VPS35 retromer component.","method":"Genetic epistasis in Drosophila and rodent neurons; Co-IP; retromer complex analysis; endolysosomal sorting assays","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis across two model organisms plus biochemical validation","pmids":["23395371"],"is_preprint":false},{"year":2014,"finding":"LRRK2 negatively regulates PKA activity in striatal projection neurons (SPNs) by interacting with PKA regulatory subunit IIβ (PKARIIβ); loss of LRRK2 promotes synaptic translocation of PKA and increases PKA-mediated phosphorylation of cofilin and GluR1, causing abnormal synaptogenesis; the R1441C mutation impairs LRRK2-PKARIIβ interaction, inducing excessive PKA activity.","method":"Co-IP of LRRK2 with PKARIIβ; PKA activity assays; phosphorylation of cofilin and GluR1 in Lrrk2-/- and R1441C mice; synaptic translocation imaging","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus functional PKA activity measurements in KO and knock-in mice","pmids":["24464040"],"is_preprint":false},{"year":2015,"finding":"LRRK2 binds to focal adhesion kinase (FAK) and phosphorylates its Thr-X-Arg/Lys (TXR/K) motifs, attenuating FAK activity (decreased pY397 phosphorylation); G2019S-LRRK2 decreases pY397-FAK levels in brain, microglia, and HEK cells and retards ADP-induced microglial motility; LRRK2 kinase inhibition restores pY397 levels and rescues microglial motility.","method":"Co-IP of LRRK2 with FAK; in vitro kinase assays; phosphorylation assays; live-cell motility assays with G2019S transgenic microglia; LRRK2 kinase inhibitor rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — Co-IP plus direct kinase assay plus functional motility rescue in transgenic cells","pmids":["26365310"],"is_preprint":false},{"year":2015,"finding":"LRRK2 kinase inhibition (PF-06447475) is well tolerated in rats and provides neuroprotection against α-synuclein-induced dopaminergic neurodegeneration; G2019S-LRRK2 exacerbates dopaminergic neurodegeneration and inflammation in response to α-synuclein overexpression, and both are mitigated by LRRK2 kinase inhibition.","method":"AAV-mediated α-synuclein overexpression in rat substantia nigra; LRRK2 kinase inhibitor treatment; stereological dopaminergic neuron counting; inflammatory marker assessment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — pharmacological intervention with defined neuronal phenotype in vivo","pmids":["26078453"],"is_preprint":false},{"year":2015,"finding":"LRRK2 facilitates tau phosphorylation as a scaffold protein rather than as a direct tau kinase; LRRK2 binds tau 140-200-fold more strongly than cdk5 but has 250-480-fold lower specific activity than cdk5 on tau; cdk5 and tau co-immunoprecipitate with endogenous LRRK2; LRRK2 knockdown reduces tau phosphorylation at Ser396/Ser404 without affecting kinase inhibitor-sensitive sites.","method":"In vitro kinase assays comparing LRRK2 and cdk5; binding affinity measurements; Co-IP of endogenous LRRK2 with tau and cdk5 in SH-SY5Y cells and mouse brain; LRRK2 siRNA knockdown","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro kinase assay, binding measurements, endogenous Co-IP, and siRNA knockdown","pmids":["26268594"],"is_preprint":false},{"year":2016,"finding":"Phosphoproteomics identified a subset of Rab GTPases (Rab3A/B/C/D, Rab5A/B, Rab8A/B, Rab10, Rab12, Rab29, Rab35, Rab43) as bona fide physiological LRRK2 substrates; LRRK2 directly phosphorylates a conserved Thr/Ser residue in the switch-II domain in vivo and in vitro; pathogenic LRRK2 variants increase Rab phosphorylation; phosphorylation strongly decreases Rab affinity to GDP dissociation inhibitors (GDIs).","method":"Quantitative phosphoproteomics; genetics (KO cells); pharmacology (LRRK2 inhibitors); in vitro kinase assays; GDI binding assays","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 — unbiased phosphoproteomics with genetic and pharmacological validation, in vitro confirmation; highly cited foundational study","pmids":["26824392"],"is_preprint":false},{"year":2016,"finding":"LRRK2 negatively regulates α-synuclein clearance by microglia; LRRK2-KO microglia take up and clear α-synuclein more effectively than WT, associated with increased Rab5-positive early endosomes and enhanced Rab5-dynamin 1 interaction, indicating LRRK2 negatively regulates endocytosis.","method":"LRRK2-KO mouse microglia; α-synuclein uptake assays; Rab5/Rab7/Rab11 immunostaining; Rab5-dynamin 1 Co-IP","journal":"BMC neuroscience","confidence":"Medium","confidence_rationale":"Tier 2-3 — KO phenotype with endosomal marker characterization, single lab","pmids":["27903237"],"is_preprint":false},{"year":2016,"finding":"LRRK2 interacts with p62/SQSTM-1, a selective autophagic receptor; p62 overexpression leads to robust degradation of LRRK2 through the autophagy-lysosome pathway; LRRK2 indirectly regulates Ser351 and Ser403 phosphorylation of p62 and reduces p62-Keap1 interaction.","method":"Co-IP of LRRK2 with p62; autophagy flux assays; phosphorylation analysis of p62","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP with functional degradation assay, single lab","pmids":["27631370"],"is_preprint":false},{"year":2017,"finding":"The structural interface between LRRK2 and 14-3-3 proteins was characterized: phosphorylation of multiple LRRK2 sites (including Ser910/Ser935) enables multivalent 14-3-3 binding; PD-relevant mutations impair this interaction, which is connected to enhanced kinase activity, LRRK2 inclusion body formation, and reduced neurite length.","method":"Biochemical binding assays; crystal structures of 14-3-3 bound to LRRK2 phosphopeptides","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus biochemical validation","pmids":["28202711"],"is_preprint":false},{"year":2018,"finding":"LRRK2 kinase activity promotes mitochondrial fission in microglia via Drp1; LPS treatment increases LRRK2 protein levels and mitochondrial fission in microglia; G2019S-LRRK2 transgenic mice show decreased mitochondrial area and reduced microglial processes; LRRK2 kinase inhibition (GSK2578215A) rescues these phenotypes and reduces CD68, Drp1, and TNF-α levels.","method":"G2019S transgenic mice; primary microglia; LRRK2 kinase inhibitor treatment; mitochondrial morphology analysis; Drp1 and inflammatory marker quantification","journal":"Experimental neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 — kinase inhibitor rescue in transgenic and primary cells with defined mechanistic marker","pmids":["30022868"],"is_preprint":false},{"year":2019,"finding":"PPM1H phosphatase acts as a key counterbalance to LRRK2 signaling by selectively dephosphorylating LRRK2-phosphorylated Rab proteins; PPM1H knockout increases endogenous Rab phosphorylation; PPM1H directly and efficiently dephosphorylates Rab8A in biochemical studies; a substrate-trapping PPM1H mutant (Asp288Ala) binds with high affinity to LRRK2-phosphorylated Rabs; PPM1H is localized to the Golgi and its knockdown suppresses primary cilia formation similarly to pathogenic LRRK2.","method":"siRNA screen of all human phosphatases; PPM1H KO cells; in vitro dephosphorylation assays; substrate-trapping mutant; Golgi localization imaging; cilia formation assays","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 — unbiased siRNA screen, in vitro biochemical validation, multiple orthogonal assays","pmids":["31663853"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of the WD40 domain of human LRRK2 at 2.6-Å resolution reveals a seven-bladed WD40 fold that forms dimers in crystal and in solution; PD-associated and structure-based mutations in the WD40 domain (including G2385R) mainly compromise dimer formation; WD40 dimerization-defective mutants including G2385R show enhanced kinase activity as measured by Rab10 phosphorylation.","method":"X-ray crystallography; solution measurements of dimerization; phospho-Rab10 kinase activity assays of WD40 mutants","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional mutagenesis validation","pmids":["30635421"],"is_preprint":false},{"year":2020,"finding":"LRRK2 is recruited to lysosomes after lysosome membrane rupture (LLOME exposure) and mediates lysosomal tubulation/sorting (LYTL); LRRK2 recruits motor adaptor JIP4 to lysosomes in a kinase-dependent manner via phosphorylation of RAB35 and RAB10; JIP4 promotes formation of LAMP1-negative tubules that release membranous vesicles from lysosomes.","method":"Unbiased proteomic screen (APEX proximity labeling); super-resolution live-cell imaging; FIB-SEM; LRRK2 kinase inhibitors; RAB phosphorylation assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1-2 — unbiased proteomics, super-resolution imaging, FIB-SEM structural validation, kinase-dependent rescue","pmids":["33177079"],"is_preprint":false},{"year":2020,"finding":"Lysosomal stress agents (lysosomotropic drugs, nigericin, monensin, chloroquine, LLOMe) potently stimulate LRRK2-dependent Rab10 phosphorylation and promote formation of LRRK2-coated enlarged lysosomes; this upregulation occurs not by increasing LRRK2 enzymatic activity per se but by enhancing molecular proximity between LRRK2 and Rab GTPase substrates on lysosomal surfaces; the effect is downstream of Rab29-mediated LRRK2 activation.","method":"Lysosomal stress agent treatment; Rab10 phosphorylation assays; LRRK2 autophosphorylation at Ser1292; proximity measurements; Rab29 KO cells","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 2 — multiple pharmacological and genetic perturbations with mechanistic dissection","pmids":["32919031"],"is_preprint":false},{"year":2020,"finding":"LRRK2-mediated hyperphosphorylation of RAB proteins recruits SPAG9/JIP4 to autophagosomal membranes; increased JIP4 on autophagosomes induces abnormal kinesin-1 recruitment and activation, creating an unproductive tug-of-war between anterograde and retrograde motors that impairs processive autophagosome transport and maturation in axons.","method":"Live-cell imaging of autophagosome transport in neurons; G2019S-LRRK2 expression; kinase-dependent rescue; kinesin-1 and JIP4 co-localization assays","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — live imaging with kinase-dependent mechanistic dissection, single lab","pmids":["34110246"],"is_preprint":false},{"year":2020,"finding":"Rab29 knockout does not influence basal endogenous LRRK2 activity (Rab10 and Rab12 phosphorylation) in wild-type, R1441C knock-in, or VPS35[D620N] knock-in mice or primary cells; nigericin induces the greatest increase (5-9-fold) in Rab10/Rab12 phosphorylation in a LRRK2 inhibitor-sensitive but Rab29-independent manner.","method":"Rab29 KO mice; Rab10/Rab12 phosphorylation assays in brain and fibroblasts; lysosomal stress agents; LRRK2 inhibitors","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 — genetic KO across multiple tissues and genotypes with pharmacological validation","pmids":["33135724"],"is_preprint":false},{"year":2021,"finding":"Type I LRRK2 inhibitors (binding closed kinase conformation) and Type II inhibitors (binding open conformation) both suppress phosphorylation of Rab10 and Rab12 and promote mitophagy; Type II inhibitors fail to induce dephosphorylation of N-terminal biomarker phosphosites (Ser935), demonstrating that these biomarker sites report on kinase conformation (open vs. closed) rather than catalytic activity per se.","method":"Rab10/Rab12 phosphorylation assays; mitophagy assays; Ser935 dephosphorylation; LRRK2[A2016T] resistance mutant validation","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1-2 — systematic comparison of inhibitor classes with mechanistic dissection using resistance mutant","pmids":["34515301"],"is_preprint":false},{"year":2022,"finding":"Cryo-EM structure of the catalytic half of LRRK2 (kinase in closed conformation + GTPase domains) bound to microtubules was determined; specific residues in LRRK2's GTPase domain mediate microtubule binding; mutation of these residues disrupts microtubule binding in vitro and in cells without affecting kinase activity; LRRK1, though structurally similar, does not interact with microtubules.","method":"Cryo-EM structure determination; in vitro microtubule binding assays; mutagenesis; cell-based co-localization assays","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure with mutagenesis validation in vitro and in cells","pmids":["36510024"],"is_preprint":false},{"year":2022,"finding":"LRRK2 activation and Rab10 phosphorylation at lysosomes is regulated by lysosomal positioning; anterograde transport of lysosomes to the cell periphery (via ARL8B/SKIP overexpression or JIP4 knockdown) blocks LRRK2-dependent Rab10 recruitment and phosphorylation and prevents LYTL lysosomal tubulation; perinuclear lysosomal clustering (via RILP overexpression) increases LRRK2-dependent Rab10 phosphorylation; PPM1H knockdown significantly increases pRab10 and lysosomal tubulation.","method":"Directed LRRK2 localization system; ARL8B/SKIP overexpression; RILP overexpression; JIP4 KD; PPM1H KD; super-resolution imaging of pRab10 and lysosomal tubulation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal genetic perturbations with imaging readout demonstrating spatial regulation","pmids":["36256825"],"is_preprint":false},{"year":2022,"finding":"Directing LRRK2 to any membrane of the endolysosomal pathway (Golgi, lysosomes, plasma membrane, recycling/early/late endosomes) via rapamycin-dependent oligomerization is sufficient to trigger local accumulation of phosphorylated RAB10, RAB12, and JIP4 recruitment, irrespective of membrane identity; endogenous Rab29 is not required for LRRK2 activation at Golgi or lysosomes.","method":"Rapamycin-dependent LRRK2 targeting to specific organelles; phospho-RAB10/RAB12 immunofluorescence; JIP4 recruitment; Rab29 KO validation","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 2 — systematic organelle targeting with multiple readouts and genetic controls","pmids":["35580815"],"is_preprint":false},{"year":2023,"finding":"Rab12 is a novel modulator of LRRK2-dependent Rab10 phosphorylation; Rab12 is recruited to damaged lysosomes and drives local LRRK2-dependent increases in Rab10 phosphorylation at the lysosome; PD-linked variants LRRK2 R1441G and VPS35 D620N increase LRRK2 recruitment to lysosomes and elevate lysosomal pT73-Rab10 levels.","method":"siRNA screen; lysosome immunopurification; imaging of Rab12 recruitment; Rab10 phosphorylation assays; PD knock-in variants","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — siRNA screen with mechanistic follow-up using lysosome isolation and PD variants","pmids":["37874617"],"is_preprint":false},{"year":2025,"finding":"STING signaling activates LRRK2 kinase activity at lysosomes through the CASM (conjugation of ATG8 to single membranes) pathway; multiple stimuli that perturb lysosomal homeostasis converge on CASM to activate LRRK2; LRRK2 lysosome recruitment and kinase activation are highly dependent on interactions with GABARAP (an ATG8 family member) rather than other ATG8 proteins.","method":"STING agonist treatment; CASM pathway perturbation; GABARAP interaction assays; LRRK2 lysosome recruitment imaging; Rab phosphorylation as kinase activity readout","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple stimuli and pathway perturbations with specific protein interaction identified","pmids":["39812709"],"is_preprint":false},{"year":2014,"finding":"Mutant LRRK2 (G2019S and R1441C) expression in cortical neurons increases whole-cell current responses to AMPA and NMDA receptor agonists, increases frequency of spontaneous miniature EPSCs, and increases excitatory synapse density; mutant neurons show enhanced vulnerability to synaptic glutamate stress; NMDA receptor antagonist memantine protects against dendrite degeneration caused by mutant LRRK2.","method":"Whole-cell voltage clamp in cultured rat cortical neurons; mEPSC recordings; immunofluorescence for PSD95/VGLUT1; pharmacological rescue with memantine","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — electrophysiology with defined synaptic phenotype and pharmacological rescue, single lab","pmids":["24874075"],"is_preprint":false},{"year":2015,"finding":"LRRK2 promotes accumulation of non-monomeric and high-molecular-weight Tau species and increases Tau secretion independently of LRRK2 kinase activity, possibly through impairment of Tau proteasomal degradation; LRRK2 directly interacts with Tau.","method":"Co-IP of LRRK2 with Tau; size-exclusion/native PAGE analysis of Tau species; proteasome activity assays; Tau secretion measurement","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP with functional Tau species analysis, single lab","pmids":["26014385"],"is_preprint":false},{"year":2009,"finding":"The R1441C mutant form of LRRK2 (expressed from a genomic DNA YPet-LRRK2 reporter) induces impaired autophagic balance at the endocytic-autophagic crossroads; conversely, RNAi-induced knockdown of LRRK2 increases autophagic activity, demonstrating that LRRK2 acts as a negative regulator of autophagic activity.","method":"Genomic DNA reporter (STEP recombineering); autophagic flux assays; RNAi knockdown","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2-3 — gain and loss-of-function with autophagic flux readout, single lab","pmids":["19770575"],"is_preprint":false},{"year":2020,"finding":"R1441C and G2019S LRRK2 knock-in mutations increase levels and alter nanoscale organization of glutamatergic AMPA receptors at synapses of striatal projection neurons; these mutations decrease frequency of miniature EPSCs and alter dendritic spine nano-architecture, with effects exaggerated in direct pathway SPNs for R1441C.","method":"Super-resolution imaging (STORM); biochemical synaptic fractionation; miniature EPSC recordings; two-photon glutamate uncaging","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 — super-resolution structural imaging plus electrophysiology in knock-in mice","pmids":["33006315"],"is_preprint":false},{"year":2011,"finding":"LRRK2 mutant iPSC-derived DA neurons show increased expression of oxidative stress-response genes and α-synuclein protein, and are more sensitive to caspase-3 activation and cell death caused by hydrogen peroxide, MG-132, and 6-hydroxydopamine compared to control DA neurons.","method":"iPSC generation from G2019S-LRRK2 patients; DA neuron differentiation; transcriptomic analysis; caspase-3 activation; cell death assays","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 — patient-derived iPSC model with multiple stress paradigms, highly cited","pmids":["21362567"],"is_preprint":false}],"current_model":"LRRK2 is a large multidomain kinase/GTPase of the ROCO family that phosphorylates a defined subset of Rab GTPases (including Rab8A, Rab10, Rab12, Rab35) on a conserved switch-II motif residue; its kinase activity is activated by membrane recruitment to endolysosomal compartments (regulated by GABARAP/CASM signaling, Rab12, and lysosomal positioning), requires GTPase domain function, depends on a dimeric assembly state, is counterbalanced by the phosphatase PPM1H, and is regulated by 14-3-3 binding to phosphorylated N-terminal sites; pathogenic PD mutations (particularly G2019S, R1441C/G, Y1699C) increase kinase activity or impair GTPase activity, leading to hyperphosphorylation of Rab substrates that disrupts vesicular trafficking, lysosomal tubulation/sorting (LYTL), autophagosome transport, synaptogenesis, microglial motility, and chaperone-mediated autophagy."},"narrative":{"teleology":[{"year":2004,"claim":"Identification of LRRK2 as the PARK8 gene established the first high-confidence causal locus for autosomal-dominant Parkinson disease and revealed its unique multidomain architecture containing both kinase (MAPKKK-class) and Roc GTPase domains.","evidence":"Positional cloning, candidate gene sequencing, and post-mortem neuropathology across dozens of PD families","pmids":["15541308","15541309"],"confidence":"High","gaps":["No enzymatic characterization yet performed","Mechanism linking mutations to neurodegeneration unknown","Physiological substrates unidentified"]},{"year":2006,"claim":"Demonstrating that PD mutations increase kinase activity and that kinase-dead versions abolish toxicity established a gain-of-function kinase mechanism as the driver of LRRK2-mediated neurodegeneration, while GTPase activity was shown to regulate kinase output.","evidence":"In vitro kinase assays with recombinant LRRK2; kinase-dead and GTPase-dead mutagenesis; neuronal toxicity and neurite length assays in primary neurons and rodent CNS","pmids":["16269541","16750377","16980962","17114044","17200152"],"confidence":"High","gaps":["Physiological kinase substrates still unknown","Mechanism of GTPase-to-kinase signal transduction unclear","No structural information on any domain"]},{"year":2007,"claim":"Characterization of LRRK2 in C. elegans and Drosophila revealed conserved roles in polarized vesicle sorting and dopaminergic neuron maintenance, placing LRRK2 squarely in the membrane trafficking pathway.","evidence":"C. elegans lrk-1 mutants with synaptic vesicle mis-sorting; Drosophila LRRK loss-of-function with DA neuron degeneration; Drosophila G2019S overexpression with dose-dependent DA neuron loss","pmids":["17346966","17498648","18258746"],"confidence":"High","gaps":["Direct mammalian trafficking substrates not identified","Mechanism of vesicle sorting regulation unresolved"]},{"year":2009,"claim":"Discovery that kinase activity resides with the LRRK2 dimer and that R1441C impairs autophagic balance linked the quaternary structure of LRRK2 to its catalytic regulation and positioned it as a negative regulator of autophagy.","evidence":"Size-exclusion chromatography with kinase activity measurement of separated fractions; autophagic flux assays with LRRK2 knockdown and R1441C expression","pmids":["19826009","19770575"],"confidence":"High","gaps":["Structural basis of dimerization unknown","Autophagic substrates or effectors not identified"]},{"year":2013,"claim":"Two parallel discoveries—that LRRK2 is degraded by and inhibits chaperone-mediated autophagy (CMA), and that RAB7L1 genetically interacts with LRRK2 in endolysosomal sorting—converged to define the endolysosomal system as the principal cellular context for LRRK2 function and dysfunction.","evidence":"CMA lysosomal binding assays in iPSC-derived DA neurons, transgenic mice, and PD brain; genetic epistasis of Rab7L1 and LRRK2 in Drosophila and rodent neurons with retromer analysis","pmids":["23455607","23395371"],"confidence":"High","gaps":["Direct LRRK2-Rab interaction mechanism unknown","Retromer connection not mechanistically resolved"]},{"year":2014,"claim":"LRRK2 was found to scaffold PKA signaling in striatal neurons, with loss of function or the R1441C mutation causing excessive PKA-mediated phosphorylation of synaptic targets (cofilin, GluR1) and abnormal synaptogenesis, revealing a kinase-independent scaffolding role at synapses.","evidence":"Co-IP of LRRK2 with PKARIIβ; PKA activity assays in Lrrk2-KO and R1441C knock-in mice; synapse imaging","pmids":["24464040"],"confidence":"High","gaps":["Whether PKA scaffolding is independent of or linked to Rab phosphorylation unclear","Synaptic phenotype not tested with kinase inhibitors"]},{"year":2016,"claim":"Unbiased phosphoproteomics identified a defined subset of Rab GTPases as bona fide LRRK2 substrates phosphorylated on a conserved switch-II residue, fundamentally redefining the LRRK2 signaling pathway and providing the first pharmacodynamic biomarkers for kinase activity.","evidence":"Quantitative phosphoproteomics in KO cells and with LRRK2 inhibitors; in vitro kinase assays; GDI binding assays showing phosphorylation impairs Rab recycling","pmids":["26824392"],"confidence":"High","gaps":["Functional consequences of individual Rab phosphorylation events largely uncharacterized","Relative contribution of each Rab substrate to disease unclear"]},{"year":2019,"claim":"Two structural milestones—the WD40 domain crystal structure revealing a dimerization interface disrupted by PD variants, and identification of PPM1H as the opposing phosphatase for LRRK2-phosphorylated Rabs—defined the structural basis of kinase regulation and the signaling off-switch.","evidence":"X-ray crystallography of WD40 domain with mutagenesis; unbiased siRNA phosphatase screen identifying PPM1H; in vitro dephosphorylation and cilia formation assays","pmids":["30635421","31663853"],"confidence":"High","gaps":["Full-length LRRK2 structure not yet determined","PPM1H regulation in disease contexts not explored","PPM1H-LRRK2 interplay at lysosomes not established"]},{"year":2020,"claim":"LRRK2 was shown to be recruited to stressed lysosomes where it phosphorylates Rab10/Rab35 and recruits the motor adaptor JIP4 to drive lysosomal tubulation/sorting (LYTL), establishing the core effector mechanism downstream of Rab phosphorylation; separately, lysosomal positioning was found to regulate LRRK2 activation, and forced membrane recruitment to any endolysosomal compartment was sufficient to activate the pathway.","evidence":"APEX proximity proteomics; super-resolution and FIB-SEM imaging of lysosomal tubules; rapamycin-induced membrane targeting; lysosomal positioning perturbations (ARL8B/RILP); Rab29-KO mice","pmids":["33177079","32919031","35580815","36256825","33135724"],"confidence":"High","gaps":["Cargo sorted by LYTL tubules not defined","Physiological triggers of lysosomal LRRK2 recruitment in neurons incompletely understood","Rab29 dispensability conflicts with earlier overexpression data"]},{"year":2022,"claim":"Cryo-EM structure of the LRRK2 catalytic half bound to microtubules revealed the GTPase domain mediates microtubule interaction independently of kinase activity, providing the first near-atomic structural framework for understanding LRRK2 filament formation on microtubules seen with pathogenic mutants and Type I kinase inhibitors.","evidence":"Cryo-EM at sub-nanometer resolution; mutagenesis of microtubule-binding residues validated in vitro and in cells","pmids":["36510024"],"confidence":"High","gaps":["Full-length dimeric LRRK2 structure with regulatory domains still lacking","Functional significance of microtubule decoration in neurons debated"]},{"year":2023,"claim":"Rab12 was identified as a novel upstream modulator that recruits LRRK2 to damaged lysosomes and potentiates local Rab10 phosphorylation, clarifying the feed-forward amplification loop at lysosomes.","evidence":"siRNA screen; lysosome immunopurification; imaging of Rab12 recruitment; validation with LRRK2 R1441G and VPS35 D620N knock-in variants","pmids":["37874617"],"confidence":"High","gaps":["Whether Rab12 is phosphorylated before or after LRRK2 recruitment unclear","Redundancy among Rab substrates in recruitment not resolved"]},{"year":2025,"claim":"The CASM (conjugation of ATG8 to single membranes) pathway, activated by STING signaling and other lysosomal perturbations, was identified as a major upstream regulator of LRRK2 lysosomal recruitment, with GABARAP specifically mediating LRRK2 membrane engagement.","evidence":"STING agonist treatment; CASM pathway perturbation; GABARAP interaction assays; Rab phosphorylation readouts","pmids":["39812709"],"confidence":"High","gaps":["Structural basis of LRRK2-GABARAP interaction not resolved","Whether CASM-LRRK2 axis operates in neurons and microglia in vivo not demonstrated"]},{"year":null,"claim":"Key unresolved questions include the full-length structure of dimeric LRRK2 in active versus autoinhibited states, the identity of cargoes sorted by LYTL tubules, the relative pathogenic contributions of individual Rab substrate phosphorylation events, and whether therapeutic kinase inhibition can reverse disease-relevant phenotypes in humans without adverse effects from on-target lysosomal or pulmonary toxicity.","evidence":"","pmids":[],"confidence":"High","gaps":["Full-length active/autoinhibited LRRK2 dimer structure missing","LYTL tubule cargo identity unknown","Therapeutic window for kinase inhibition in humans not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,3,4,5,6,7,17,20,26,27]},{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[4,7,13]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[16,19]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[2,6,17,20,27]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[14,27,28,33,34,35,36]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[8,34]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[15,34]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[32]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[27,29,34]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[8,15,20,27,33,34,35]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[14,22,29,39]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[16,20,25,36]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[5,9,10,37,40]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,41]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[27,28,33,35]}],"complexes":[],"partners":["RAB10","RAB12","RAB8A","RAB35","SPAG9","PPM1H","GABARAP","ARFGAP1"],"other_free_text":[]},"mechanistic_narrative":"LRRK2 is a large multidomain ROCO-family enzyme that integrates serine/threonine kinase and GTPase activities to regulate endolysosomal membrane trafficking, autophagy, and neuronal integrity. Its principal physiological substrates are a subset of Rab GTPases (Rab8A, Rab10, Rab12, Rab35 and others), which LRRK2 phosphorylates on a conserved switch-II residue in a reaction that requires GTP-bound Roc domain activity, dimeric assembly, and membrane recruitment to endolysosomal compartments—a process governed by the CASM/GABARAP pathway, lysosomal positioning, and counterbalanced by the phosphatase PPM1H [PMID:26824392, PMID:33177079, PMID:31663853, PMID:36256825, PMID:39812709]. Phosphorylated Rabs recruit the motor adaptor JIP4, driving lysosomal tubulation/sorting (LYTL) and modulating autophagosome transport; pathogenic Parkinson disease mutations (G2019S, R1441C/G, Y1699C) increase kinase output or impair GTPase hydrolysis, leading to Rab hyperphosphorylation that disrupts vesicular trafficking, synaptic organization, microglial motility, and chaperone-mediated autophagy [PMID:33177079, PMID:34110246, PMID:23455607, PMID:26365310, PMID:33006315]. Mutations in LRRK2 are the most common genetic cause of familial Parkinson disease (PARK8 locus), with gain-of-function kinase activity required for neurotoxicity and amenable to pharmacological inhibition [PMID:15541308, PMID:16750377, PMID:26078453]."},"prefetch_data":{"uniprot":{"accession":"Q5S007","full_name":"Leucine-rich repeat serine/threonine-protein kinase 2","aliases":["Dardarin"],"length_aa":2527,"mass_kda":286.1,"function":"Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:17114044, PubMed:20949042, PubMed:21850687, PubMed:22012985, PubMed:23395371, PubMed:24687852, PubMed:25201882, PubMed:26014385, PubMed:26824392, PubMed:27830463, PubMed:28720718, PubMed:29125462, PubMed:29127255, PubMed:29212815, PubMed:30398148, PubMed:30635421). Is a key regulator of RAB GTPases by regulating the GTP/GDP exchange and interaction partners of RABs through phosphorylation (PubMed:26824392, PubMed:28720718, PubMed:29125462, PubMed:29127255, PubMed:29212815, PubMed:30398148, PubMed:30635421). Phosphorylates RAB3A, RAB3B, RAB3C, RAB3D, RAB5A, RAB5B, RAB5C, RAB8A, RAB8B, RAB10, RAB12, RAB29, RAB35, and RAB43 (PubMed:23395371, PubMed:26824392, PubMed:28720718, PubMed:29125462, PubMed:29127255, PubMed:29212815, PubMed:30398148, PubMed:30635421, PubMed:38127736). Regulates the RAB3IP-catalyzed GDP/GTP exchange for RAB8A through the phosphorylation of 'Thr-72' on RAB8A (PubMed:26824392). Inhibits the interaction between RAB8A and GDI1 and/or GDI2 by phosphorylating 'Thr-72' on RAB8A (PubMed:26824392). Regulates primary ciliogenesis through phosphorylation of RAB8A and RAB10, which promotes SHH signaling in the brain (PubMed:29125462, PubMed:30398148). Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose-6-phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner (PubMed:23395371). Regulates neuronal process morphology in the intact central nervous system (CNS) (PubMed:17114044). Plays a role in synaptic vesicle trafficking (PubMed:24687852). Plays an important role in recruiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization (PubMed:25201882). Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway (PubMed:22012985). The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes (PubMed:22012985). Phosphorylates PRDX3 (PubMed:21850687). By phosphorylating APP on 'Thr-743', which promotes the production and the nuclear translocation of the APP intracellular domain (AICD), regulates dopaminergic neuron apoptosis (PubMed:28720718). Acts as a positive regulator of innate immunity by mediating phosphorylation of RIPK2 downstream of NOD1 and NOD2, thereby enhancing RIPK2 activation (PubMed:27830463). Independent of its kinase activity, inhibits the proteasomal degradation of MAPT, thus promoting MAPT oligomerization and secretion (PubMed:26014385). In addition, has GTPase activity via its Roc domain which regulates LRRK2 kinase activity (PubMed:18230735, PubMed:26824392, PubMed:28720718, PubMed:29125462, PubMed:29212815). Recruited by RAB29/RAB7L1 to overloaded lysosomes where it phosphorylates and stabilizes RAB8A and RAB10 which promote lysosomal content release and suppress lysosomal enlargement through the EHBP1 and EHBP1L1 effector proteins (PubMed:30209220, PubMed:38227290)","subcellular_location":"Cytoplasmic vesicle; Perikaryon; Golgi apparatus membrane; Cell projection, axon; Cell projection, dendrite; Endoplasmic reticulum membrane; Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane; Endosome; Lysosome; Mitochondrion outer membrane; Cytoplasm, cytoskeleton; Cytoplasmic vesicle, phagosome","url":"https://www.uniprot.org/uniprotkb/Q5S007/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LRRK2","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LRRK2","total_profiled":1310},"omim":[{"mim_id":"620923","title":"PARKINSON DISEASE 26, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK26","url":"https://www.omim.org/entry/620923"},{"mim_id":"619583","title":"EH DOMAIN-BINDING PROTEIN 1-LIKE 1; EHBP1L1","url":"https://www.omim.org/entry/619583"},{"mim_id":"613888","title":"RAS HOMOLOG GENE FAMILY, MEMBER T1; RHOT1","url":"https://www.omim.org/entry/613888"},{"mim_id":"613164","title":"PARKINSON DISEASE 16; PARK16","url":"https://www.omim.org/entry/613164"},{"mim_id":"613146","title":"MICRO RNA 184; MIR184","url":"https://www.omim.org/entry/613146"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Basal body","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nuclear membrane","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":49.4}],"url":"https://www.proteinatlas.org/search/LRRK2"},"hgnc":{"alias_symbol":["ROCO2","DKFZp434H2111","FLJ45829","RIPK7"],"prev_symbol":["PARK8"]},"alphafold":{"accession":"Q5S007","domains":[{"cath_id":"1.25.10,1.25.10","chopping":"249-327_350-428","consensus_level":"medium","plddt":86.1882,"start":249,"end":428},{"cath_id":"3.80.10.10","chopping":"1177-1328","consensus_level":"medium","plddt":84.17,"start":1177,"end":1328},{"cath_id":"1.10.510.10","chopping":"1951-2124","consensus_level":"high","plddt":80.3918,"start":1951,"end":2124},{"cath_id":"2.40.128.630","chopping":"2135-2150_2308-2401_2410-2527","consensus_level":"medium","plddt":80.9411,"start":2135,"end":2527},{"cath_id":"1.25.40","chopping":"477-515_532-595","consensus_level":"medium","plddt":81.9647,"start":477,"end":595}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5S007","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q5S007-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q5S007-F1-predicted_aligned_error_v6.png","plddt_mean":77.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LRRK2","jax_strain_url":"https://www.jax.org/strain/search?query=LRRK2"},"sequence":{"accession":"Q5S007","fasta_url":"https://rest.uniprot.org/uniprotkb/Q5S007.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q5S007/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5S007"}},"corpus_meta":[{"pmid":"15541308","id":"PMC_15541308","title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.","date":"2004","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/15541308","citation_count":1873,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23455607","id":"PMC_23455607","title":"Interplay of LRRK2 with chaperone-mediated autophagy.","date":"2013","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23455607","citation_count":493,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15880653","id":"PMC_15880653","title":"An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family.","date":"2005","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15880653","citation_count":218,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18258746","id":"PMC_18258746","title":"A Drosophila model for LRRK2-linked parkinsonism.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18258746","citation_count":215,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33177079","id":"PMC_33177079","title":"LRRK2 mediates tubulation and vesicle sorting from lysosomes.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33177079","citation_count":201,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17623048","id":"PMC_17623048","title":"Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17623048","citation_count":200,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25391693","id":"PMC_25391693","title":"The role of the LRRK2 gene in Parkinsonism.","date":"2014","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/25391693","citation_count":181,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16437584","id":"PMC_16437584","title":"Biochemical and pathological characterization of Lrrk2.","date":"2006","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16437584","citation_count":179,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24464040","id":"PMC_24464040","title":"LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.","date":"2014","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24464040","citation_count":169,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26078453","id":"PMC_26078453","title":"Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26078453","citation_count":168,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30837320","id":"PMC_30837320","title":"LRRK2 links genetic and sporadic Parkinson's disease.","date":"2019","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/30837320","citation_count":167,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19826009","id":"PMC_19826009","title":"Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19826009","citation_count":152,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27927216","id":"PMC_27927216","title":"LRRK2 at the interface of autophagosomes, endosomes and lysosomes.","date":"2016","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/27927216","citation_count":142,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17346966","id":"PMC_17346966","title":"LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins.","date":"2007","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/17346966","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16966681","id":"PMC_16966681","title":"The Parkinson disease gene LRRK2: evolutionary and structural insights.","date":"2006","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/16966681","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19847307","id":"PMC_19847307","title":"Metabolomic profiling in LRRK2-related Parkinson's disease.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19847307","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25899482","id":"PMC_25899482","title":"Cellular processes associated with LRRK2 function and dysfunction.","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/25899482","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29473513","id":"PMC_29473513","title":"The Role of LRRK2 in Neurodegeneration of Parkinson Disease.","date":"2018","source":"Current neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29473513","citation_count":133,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29309488","id":"PMC_29309488","title":"Progression in the LRRK2-Asssociated Parkinson Disease Population.","date":"2018","source":"JAMA neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29309488","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17498648","id":"PMC_17498648","title":"Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17498648","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28764903","id":"PMC_28764903","title":"Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.","date":"2017","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28764903","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34991886","id":"PMC_34991886","title":"LRRK2 and idiopathic Parkinson's disease.","date":"2022","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34991886","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31769472","id":"PMC_31769472","title":"LRRK2 regulation of immune-pathways and inflammatory disease.","date":"2019","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/31769472","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32523507","id":"PMC_32523507","title":"\"LRRK2: Autophagy and Lysosomal Activity\".","date":"2020","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32523507","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23938341","id":"PMC_23938341","title":"LRRK2: cause, risk, and mechanism.","date":"2013","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/23938341","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23066449","id":"PMC_23066449","title":"Brain Penetrant LRRK2 Inhibitor.","date":"2012","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/23066449","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28028237","id":"PMC_28028237","title":"Nrf2 mitigates LRRK2- and α-synuclein-induced neurodegeneration by modulating proteostasis.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28028237","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29894679","id":"PMC_29894679","title":"LRRK2 and mitochondria: Recent advances and current views.","date":"2018","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/29894679","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31663853","id":"PMC_31663853","title":"PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31663853","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18804399","id":"PMC_18804399","title":"Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.","date":"2008","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/18804399","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26365310","id":"PMC_26365310","title":"LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26365310","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22423108","id":"PMC_22423108","title":"ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2.","date":"2012","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22423108","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33266247","id":"PMC_33266247","title":"Pathological Functions of LRRK2 in Parkinson's Disease.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33266247","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24907399","id":"PMC_24907399","title":"LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.","date":"2014","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24907399","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16406842","id":"PMC_16406842","title":"LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?","date":"2006","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16406842","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30022868","id":"PMC_30022868","title":"LRRK2 Kinase Activity Induces Mitochondrial Fission in Microglia via Drp1 and Modulates Neuroinflammation.","date":"2018","source":"Experimental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30022868","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30635421","id":"PMC_30635421","title":"Crystal structure of the WD40 domain dimer of LRRK2.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30635421","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28353276","id":"PMC_28353276","title":"Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353276","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26177462","id":"PMC_26177462","title":"Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26177462","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25650144","id":"PMC_25650144","title":"Cognitive profile of LRRK2-related Parkinson's disease.","date":"2015","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/25650144","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27220776","id":"PMC_27220776","title":"Inflammatory profile in LRRK2-associated prodromal and clinical PD.","date":"2016","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27220776","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34196120","id":"PMC_34196120","title":"LRRK2 recruitment, activity, and function in organelles.","date":"2021","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/34196120","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22441981","id":"PMC_22441981","title":"Mechanisms of LRRK2-mediated neurodegeneration.","date":"2012","source":"Current neurology and neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/22441981","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33769432","id":"PMC_33769432","title":"Parkinson's disease and mitophagy: an emerging role for LRRK2.","date":"2021","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/33769432","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19142648","id":"PMC_19142648","title":"LRRK2 and neurodegeneration.","date":"2009","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/19142648","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28202711","id":"PMC_28202711","title":"Structural interface between LRRK2 and 14-3-3 protein.","date":"2017","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/28202711","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32256311","id":"PMC_32256311","title":"The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System.","date":"2020","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32256311","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33135724","id":"PMC_33135724","title":"Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity.","date":"2020","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/33135724","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17804834","id":"PMC_17804834","title":"LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.","date":"2007","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17804834","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32919031","id":"PMC_32919031","title":"Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation.","date":"2020","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32919031","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29408508","id":"PMC_29408508","title":"Role of LRRK2 in manganese-induced neuroinflammation and microglial autophagy.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29408508","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28202669","id":"PMC_28202669","title":"The LRRK2-macroautophagy axis and its relevance to Parkinson's disease.","date":"2017","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/28202669","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32612495","id":"PMC_32612495","title":"LRRK2 Phosphorylation, More Than an Epiphenomenon.","date":"2020","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32612495","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28353279","id":"PMC_28353279","title":"Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353279","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20082991","id":"PMC_20082991","title":"Clinical features of LRRK2 parkinsonism.","date":"2009","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/20082991","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22988866","id":"PMC_22988866","title":"The GTPase function of LRRK2.","date":"2012","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22988866","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28353280","id":"PMC_28353280","title":"LRRK2 and Autophagy.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353280","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28353282","id":"PMC_28353282","title":"LRRK2 and the Immune System.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353282","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34515301","id":"PMC_34515301","title":"Impact of Type II LRRK2 inhibitors on signaling and mitophagy.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34515301","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30761591","id":"PMC_30761591","title":"Higher urate in LRRK2 mutation carriers resistant to Parkinson disease.","date":"2019","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30761591","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20173330","id":"PMC_20173330","title":"LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins.","date":"2010","source":"Neuro-degenerative diseases","url":"https://pubmed.ncbi.nlm.nih.gov/20173330","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27903237","id":"PMC_27903237","title":"Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia.","date":"2016","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27903237","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24025585","id":"PMC_24025585","title":"Contribution of GTPase activity to LRRK2-associated Parkinson disease.","date":"2013","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/24025585","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36256825","id":"PMC_36256825","title":"Lysosomal positioning regulates Rab10 phosphorylation at LRRK2+ lysosomes.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36256825","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31920513","id":"PMC_31920513","title":"Autophagy and LRRK2 in the Aging Brain.","date":"2019","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31920513","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19770575","id":"PMC_19770575","title":"Parkinson disease, LRRK2 and the endocytic-autophagic pathway.","date":"2009","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/19770575","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30578345","id":"PMC_30578345","title":"The role of LRRK2 in cell signalling.","date":"2018","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/30578345","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16758483","id":"PMC_16758483","title":"Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease.","date":"2006","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/16758483","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18097165","id":"PMC_18097165","title":"Mutations in LRRK2 as a cause of Parkinson's disease.","date":"2007","source":"Neuro-Signals","url":"https://pubmed.ncbi.nlm.nih.gov/18097165","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30467121","id":"PMC_30467121","title":"LRRK2 and Rab GTPases.","date":"2018","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/30467121","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26014385","id":"PMC_26014385","title":"LRRK2 Promotes Tau Accumulation, Aggregation and Release.","date":"2015","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26014385","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22988873","id":"PMC_22988873","title":"Phosphorylation of LRRK2: from kinase to substrate.","date":"2012","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22988873","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18098275","id":"PMC_18098275","title":"Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening.","date":"2008","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/18098275","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39812709","id":"PMC_39812709","title":"A STING-CASM-GABARAP pathway activates LRRK2 at lysosomes.","date":"2025","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/39812709","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33197196","id":"PMC_33197196","title":"Selective Inhibitors of G2019S-LRRK2 Kinase Activity.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33197196","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33006315","id":"PMC_33006315","title":"Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33006315","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32736291","id":"PMC_32736291","title":"Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/32736291","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22988878","id":"PMC_22988878","title":"An emerging role for LRRK2 in the immune system.","date":"2012","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22988878","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24874075","id":"PMC_24874075","title":"Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24874075","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27631370","id":"PMC_27631370","title":"Interplay between Leucine-Rich Repeat Kinase 2 (LRRK2) and p62/SQSTM-1 in Selective Autophagy.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27631370","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31813996","id":"PMC_31813996","title":"G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.","date":"2020","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31813996","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36510024","id":"PMC_36510024","title":"Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules.","date":"2022","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/36510024","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30915830","id":"PMC_30915830","title":"LRRK2 in Infection: Friend or Foe?","date":"2019","source":"ACS infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/30915830","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27975167","id":"PMC_27975167","title":"LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.","date":"2016","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27975167","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28353287","id":"PMC_28353287","title":"Mechanisms of Mutant LRRK2 Neurodegeneration.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353287","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35580815","id":"PMC_35580815","title":"Directing LRRK2 to membranes of the endolysosomal pathway triggers RAB phosphorylation and JIP4 recruitment.","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35580815","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31138985","id":"PMC_31138985","title":"Rab GTPases as Physiological Substrates of LRRK2 Kinase.","date":"2019","source":"Experimental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31138985","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32247534","id":"PMC_32247534","title":"Leucine-rich repeat kinase-2 (LRRK2) modulates microglial phenotype and dopaminergic neurodegeneration.","date":"2020","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/32247534","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30048714","id":"PMC_30048714","title":"The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.","date":"2018","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30048714","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29308544","id":"PMC_29308544","title":"The LRRK2 signalling system.","date":"2018","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/29308544","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22077787","id":"PMC_22077787","title":"Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.","date":"2011","source":"Journal of neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22077787","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28202680","id":"PMC_28202680","title":"Cross-talk between LRRK2 and PKA: implication for Parkinson's disease?","date":"2017","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/28202680","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37874617","id":"PMC_37874617","title":"Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/37874617","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25897865","id":"PMC_25897865","title":"Structural Characterization of LRRK2 Inhibitors.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25897865","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22166430","id":"PMC_22166430","title":"Mouse models for LRRK2 Parkinson's disease.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22166430","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28353288","id":"PMC_28353288","title":"Small-Molecule Inhibitors of LRRK2.","date":"2017","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28353288","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32982917","id":"PMC_32982917","title":"Mitochondrial Mechanisms of LRRK2 G2019S Penetrance.","date":"2020","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32982917","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21603132","id":"PMC_21603132","title":"Models for LRRK2-Linked Parkinsonism.","date":"2011","source":"Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/21603132","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26268594","id":"PMC_26268594","title":"LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26268594","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34110246","id":"PMC_34110246","title":"Hyperactive LRRK2 kinase impairs the trafficking of axonal autophagosomes.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34110246","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23128233","id":"PMC_23128233","title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23128233","citation_count":3725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15541309","id":"PMC_15541309","title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.","date":"2004","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/15541309","citation_count":2368,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18587394","id":"PMC_18587394","title":"Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18587394","citation_count":2108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21102463","id":"PMC_21102463","title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21102463","citation_count":2036,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19915575","id":"PMC_19915575","title":"Genome-wide association study reveals genetic risk underlying Parkinson's disease.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19915575","citation_count":1562,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25064009","id":"PMC_25064009","title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25064009","citation_count":1512,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24252804","id":"PMC_24252804","title":"The role of oxidative stress in Parkinson's disease.","date":"2013","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/24252804","citation_count":1396,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18539534","id":"PMC_18539534","title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.","date":"2008","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18539534","citation_count":1215,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19915576","id":"PMC_19915576","title":"Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19915576","citation_count":1077,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16269541","id":"PMC_16269541","title":"Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16269541","citation_count":984,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26824392","id":"PMC_26824392","title":"Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26824392","citation_count":808,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21292315","id":"PMC_21292315","title":"Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.","date":"2011","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21292315","citation_count":748,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20711177","id":"PMC_20711177","title":"Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20711177","citation_count":624,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15680457","id":"PMC_15680457","title":"A common LRRK2 mutation in idiopathic Parkinson's disease.","date":"2005","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15680457","citation_count":621,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16750377","id":"PMC_16750377","title":"Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.","date":"2006","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/16750377","citation_count":617,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21362567","id":"PMC_21362567","title":"LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.","date":"2011","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/21362567","citation_count":569,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16436782","id":"PMC_16436782","title":"LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.","date":"2006","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16436782","citation_count":544,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20018961","id":"PMC_20018961","title":"Genomewide association study of leprosy.","date":"2009","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20018961","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16980962","id":"PMC_16980962","title":"Kinase activity of mutant LRRK2 mediates neuronal toxicity.","date":"2006","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16980962","citation_count":522,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11891824","id":"PMC_11891824","title":"A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1.","date":"2002","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11891824","citation_count":497,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17200152","id":"PMC_17200152","title":"Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17200152","citation_count":484,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17114044","id":"PMC_17114044","title":"The familial Parkinsonism gene LRRK2 regulates neurite process morphology.","date":"2006","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/17114044","citation_count":472,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26751287","id":"PMC_26751287","title":"The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer.","date":"2016","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26751287","citation_count":466,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23395371","id":"PMC_23395371","title":"RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk.","date":"2013","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/23395371","citation_count":459,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16436781","id":"PMC_16436781","title":"LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs.","date":"2006","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16436781","citation_count":450,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44420,"output_tokens":7297,"usd":0.121357},"stage2":{"model":"claude-opus-4-6","input_tokens":10999,"output_tokens":4509,"usd":0.25158},"total_usd":0.800344,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":56458,"output_tokens":11424,"usd":0.170367},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":14782,"output_tokens":3898,"usd":0.25704}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"LRRK2 was identified as the gene responsible for PARK8-linked Parkinson's disease, encoding a novel protein (dardarin) with missense mutations segregating with PD in five families.\",\n      \"method\": \"Positional cloning, genetic linkage, mutation screening\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational cloning paper, replicated across families and labs\",\n      \"pmids\": [\"15541308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LRRK2 possesses intrinsic GTPase activity (GTP binding and hydrolysis), and PD-associated R1441C/G mutations in the GTPase domain reduce GTP hydrolysis activity; GTPase activity can function independently of kinase activity, while kinase activity requires the GTPase domain.\",\n      \"method\": \"Purification of LRRK2 from transgenic mouse brain; GTP binding and hydrolysis assays; domain truncation experiments\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with purified protein and domain mutants\",\n      \"pmids\": [\"17623048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"C. elegans LRK-1 (LRRK2 ortholog) is required for polarized sorting of synaptic vesicle proteins to axons by excluding them from the AP-1/UNC-101-dependent dendritic transport pathway at the Golgi; LRK-1 localizes to the Golgi apparatus.\",\n      \"method\": \"C. elegans deletion mutant analysis, genetic epistasis with AP-1 mu1 adaptor UNC-101 and UNC-104 kinesin, fluorescence imaging of SV protein localization\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis and direct localization in vivo in ortholog\",\n      \"pmids\": [\"17346966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Expression of human LRRK2 or G2019S-LRRK2 in Drosophila dopaminergic neurons causes adult-onset selective loss of dopaminergic neurons, locomotor dysfunction, and early mortality; G2019S causes a more severe phenotype; L-DOPA improves locomotion but does not prevent neuron loss.\",\n      \"method\": \"Transgenic Drosophila GAL4/UAS system, TH immunostaining, behavioral assays, pharmacological treatment\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain-of-function model with defined cellular and behavioral phenotype\",\n      \"pmids\": [\"18258746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Loss of LRRK (Drosophila LRRK2 ortholog) causes degeneration of dopaminergic neurons and severely impaired locomotion, establishing an in vivo requirement for LRRK2 in dopaminergic neuron integrity.\",\n      \"method\": \"Drosophila LRRK loss-of-function mutants, TH immunostaining, locomotor assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean loss-of-function with defined cellular phenotype in ortholog\",\n      \"pmids\": [\"17498648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LRRK2 kinase activity is dependent on dimerization; kinase activity resides with dimeric LRRK2 (not monomers or high-MW oligomers); disruption of GTPase or kinase activity promotes oligomerization and prevents dimer formation; PD mutations that increase kinase activity increase the proportion of dimers.\",\n      \"method\": \"Size-exclusion separation of LRRK2 oligomers/dimers/monomers, in vitro kinase assay, kinase inhibitor treatment, cell-based assays\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical fractionation with kinase activity measurement, multiple methods\",\n      \"pmids\": [\"19826009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LRRK2 binds to MKK3, MKK6, MKK7, and JIP1-4 scaffold proteins, linking LRRK2 to stress kinase (MAP kinase/JNK/p38) signaling cascades; LRRK2 is associated with increased total, oligomeric, and ubiquitinated JIP levels.\",\n      \"method\": \"Co-immunoprecipitation, interaction studies in cell lines\",\n      \"journal\": \"Neuro-degenerative diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP study linking LRRK2 to stress kinase scaffolds\",\n      \"pmids\": [\"20173330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ArfGAP1 is the first identified GTPase activating protein (GAP) for LRRK2, binding via WD40 and kinase domains; ArfGAP1 increases LRRK2 GTPase activity and reduces LRRK2 toxicity; LRRK2 phosphorylates ArfGAP1 and inhibits its GAP activity; ArfGAP1 reciprocally reduces LRRK2 autophosphorylation and kinase activity.\",\n      \"method\": \"Co-IP, in vitro kinase assay, GTPase assay, Drosophila toxicity model, shRNA knockdown\",\n      \"journal\": \"Journal of Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal regulation demonstrated with in vitro enzymatic assays and in vivo validation\",\n      \"pmids\": [\"22423108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LRRK2 is degraded in lysosomes via chaperone-mediated autophagy (CMA); pathogenic mutant G2019S is poorly degraded by CMA; both WT and mutant LRRK2 interfere with CMA translocation complex organization, causing defective CMA of other substrates including α-synuclein; this LRRK2-mediated CMA inhibition is self-perpetuating.\",\n      \"method\": \"Lysosomal binding/uptake assays, CMA substrate competition assays, neuronal cultures, LRRK2 transgenic mice, iPSC-derived dopaminergic neurons, PD patient brain analysis\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods across cell, animal, and human brain models\",\n      \"pmids\": [\"23455607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LRRK2 negatively regulates PKA activity in striatal projection neurons by interacting with PKA regulatory subunit IIβ (PKARIIβ); loss of LRRK2 promotes synaptic PKA translocation and increased PKA-mediated phosphorylation of cofilin and GluR1, causing abnormal synaptogenesis; PD-linked R1441C mutation impairs LRRK2-PKARIIβ interaction, leading to excessive PKA activity.\",\n      \"method\": \"Co-IP, phosphorylation assays, Lrrk2 knockout mice, R1441C knock-in mice, confocal imaging, electrophysiology\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, KO and KI mice with defined molecular and cellular phenotypes\",\n      \"pmids\": [\"24464040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRRK2 binds to focal adhesion kinase (FAK) and phosphorylates FAK at Thr-X-Arg/Lys (TXR/K) motif(s), attenuating FAK autophosphorylation (pY397); G2019S-LRRK2 decreases pY397 in brain and microglia, impairing microglial motility.\",\n      \"method\": \"Co-IP, in vitro kinase assay, LRRK2 kinase inhibitor rescue, live-cell motility assays in G2019S transgenic microglia\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Co-IP plus in vitro kinase assay plus inhibitor rescue with functional readout\",\n      \"pmids\": [\"26365310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LRRK2 negatively regulates α-synuclein clearance in microglia by suppressing Rab5-positive endosome formation; LRRK2 knockout increases Rab5-positive endosomes and dynamin 1-Rab5 engagement, enhancing endocytic uptake and clearance of α-synuclein.\",\n      \"method\": \"LRRK2 knockout microglia, α-synuclein uptake assays, immunofluorescence for endosomal markers, co-immunoprecipitation of Rab5/dynamin 1\",\n      \"journal\": \"BMC neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — KO with mechanistic follow-up but single laboratory\",\n      \"pmids\": [\"27903237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"14-3-3 proteins interact with phosphorylated LRRK2 at multiple sites; this interaction is impaired by PD-associated mutations; loss of 14-3-3 binding is connected to enhanced LRRK2 kinase activity, LRRK2 ubiquitination, inclusion body formation, and reduced neurite length.\",\n      \"method\": \"Biochemical binding assays, crystal structure of 14-3-3/LRRK2 phosphopeptide complexes\",\n      \"journal\": \"Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures plus biochemical assays characterizing multivalent interaction\",\n      \"pmids\": [\"28202711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of the LRRK2 WD40 domain reveals a seven-bladed fold that forms a dimer; PD-associated mutations (including G2385R) mainly disrupt dimer formation; dimerization-defective WD40 mutants including G2385R enhance LRRK2 kinase activity as measured by Rab10 phosphorylation.\",\n      \"method\": \"X-ray crystallography at 2.6 Å, solution measurements, kinase activity assays (pRab10)\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation by kinase assay\",\n      \"pmids\": [\"30635421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PPM1H phosphatase specifically dephosphorylates LRRK2-phosphorylated Rab proteins (including Rab8A directly in vitro), counteracting LRRK2 signaling; PPM1H knockout increases endogenous Rab phosphorylation; PPM1H localizes to Golgi; its knockdown suppresses primary cilia formation similar to pathogenic LRRK2.\",\n      \"method\": \"siRNA screen of all human phosphatases, PPM1H KO cells, substrate-trapping mutant pulldown, in vitro dephosphorylation assay, LRRK2 inhibitor treatment, primary cilia assay\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — unbiased screen validated by in vitro reconstitution, KO, and substrate-trapping\",\n      \"pmids\": [\"31663853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LRRK2 is recruited to lysosomes after membrane rupture (LLOME treatment) and mediates lysosomal tubulation and vesicle sorting (LYTL) in a kinase-dependent manner; LRRK2 recruits the motor adaptor JIP4 to lysosomes via phosphorylation of RAB35 and RAB10; JIP4 promotes formation of LAMP1-negative tubules releasing membranous content from lysosomes.\",\n      \"method\": \"Unbiased proteomic screen, super-resolution live-cell imaging, FIB-SEM, kinase-dependent recruitment assays, RAB phosphorylation assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — proteomics plus structural imaging plus kinase-dependent functional assay, multiple orthogonal methods\",\n      \"pmids\": [\"33177079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Lysosomotropic drug-induced LRRK2 activation at lysosomes enhances Rab10 phosphorylation by increasing molecular proximity between LRRK2 and Rab substrates on the lysosomal surface (not by increasing LRRK2 autophosphorylation/enzymatic activity per se); this process is downstream of Rab29-mediated LRRK2 activation and requires LRRK2 kinase activity for cathepsin B release.\",\n      \"method\": \"Lysosomotropic drug treatments, phospho-Rab10 measurement, LRRK2 autophosphorylation assays, proximity ligation, cathepsin B release assays, Rab29 KO\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple chemical tools, KO cells, and orthogonal activity readouts\",\n      \"pmids\": [\"32919031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Endogenous Rab29 does not control basal, pathogenic mutation-driven, or lysosomal stress-stimulated LRRK2 activity (Rab10/Rab12 phosphorylation) in mouse tissues or primary cell lines; nigericin and monensin stimulate LRRK2 pathway activity independently of Rab29.\",\n      \"method\": \"Rab29 knockout mice and cells, phospho-Rab10/12 measurement, LRRK2 inhibitor treatment, Rab29 transgenic overexpression\",\n      \"journal\": \"Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO and transgenic models with endogenous activity readouts across multiple tissues\",\n      \"pmids\": [\"33135724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Hyperactive LRRK2 (G2019S) disrupts processive axonal autophagosome transport in a kinase-dependent manner by recruiting JIP4/SPAG9 (a LRRK2-phosphorylated RAB-binding motor adaptor) to the autophagosomal membrane, inducing abnormal kinesin-1 recruitment and an unproductive anterograde-retrograde motor tug-of-war; this correlates with defective autophagosome maturation.\",\n      \"method\": \"Live-cell imaging of axonal autophagosome transport, LRRK2 G2019S expression, kinase inhibitor rescue, JIP4 overexpression/knockdown, motor protein recruitment assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway established with live imaging, KD rescue, and kinase inhibitor validation\",\n      \"pmids\": [\"34110246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structure of the catalytic half of LRRK2 (kinase in closed conformation + GTPase domains) bound to microtubules; GTPase domain mediates microtubule binding; mutations in the GTPase that disrupt microtubule binding do not affect kinase activity; LRRK1, despite similar structure, does not interact with microtubules.\",\n      \"method\": \"Cryo-EM structural determination, in vitro microtubule binding assays, mutagenesis, cell-based localization assays\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure plus mutagenesis validated in vitro and in cells\",\n      \"pmids\": [\"36510024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LRRK2 activation and Rab10 phosphorylation at lysosomes is regulated by lysosomal positioning: perinuclear lysosomes support LRRK2-dependent pRab10 accumulation and LYTL tubulation, while anterograde lysosome transport (via ARL8B/SKIP overexpression or JIP4 knockdown) blocks pRab10 at the lysosomal membrane; PPM1H phosphatase in the perinuclear region counteracts pRab10.\",\n      \"method\": \"Directed LRRK2 localization constructs, lysosomal transport manipulation (ARL8B/SKIP/RILP overexpression, JIP4 KD), super-resolution imaging of pRab10/pRab12, PPM1H knockdown\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic tools with live and fixed imaging to dissect spatial regulation\",\n      \"pmids\": [\"36256825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Directing LRRK2 to any endomembrane (Golgi, lysosomes, plasma membrane, recycling/early/late endosomes) via rapamycin-inducible oligomerization is sufficient to activate LRRK2 and induce local phosphorylation of RAB10, RAB12, and JIP4 recruitment; endogenous RAB29 is not required for LRRK2 activation at Golgi or lysosome.\",\n      \"method\": \"Rapamycin-dependent LRRK2 targeting to specific organelles, phospho-RAB immunofluorescence, RAB29 KO cells\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — controlled organelle targeting system with multiple substrates and KO validation\",\n      \"pmids\": [\"35580815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Rab12 is a regulator of LRRK2 activity; Rab12 is recruited to damaged lysosomes and leads to local LRRK2-dependent increases in Rab10 phosphorylation at the lysosome; PD-linked LRRK2 R1441G and VPS35 D620N variants increase LRRK2 and pRab10 recruitment to lysosomes.\",\n      \"method\": \"Targeted siRNA screen, lysosome immunopurification, imaging, LRRK2 R1441G and VPS35 D620N knock-in models\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA screen validated by lysosome isolation and imaging across multiple PD variant models\",\n      \"pmids\": [\"37874617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"STING activation triggers LRRK2 recruitment to lysosomes and kinase activation via the CASM (conjugation of ATG8 to single membranes) pathway; multiple lysosome-perturbing stimuli converge on CASM to activate LRRK2; LRRK2 lysosomal recruitment and activation is highly dependent on GABARAP (an ATG8 family member).\",\n      \"method\": \"STING agonist treatment, CASM pathway perturbation, ATG8 lipidation assays, GABARAP interaction studies, LRRK2 recruitment and kinase activity assays\",\n      \"journal\": \"Journal of Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple stimuli tested, genetic pathway placement, specific ATG8 family member identified\",\n      \"pmids\": [\"39812709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRRK2 acts as a scaffold protein to facilitate tau phosphorylation by recruiting tau and cdk5 into a complex; LRRK2 directly phosphorylates tau at very low specific activity (480-fold lower than cdk5), while binding tau 140-fold more strongly; cdk5 and tau co-immunoprecipitate with endogenous LRRK2; LRRK2 siRNA knockdown reduces tau phosphorylation at Ser396/Ser404 independent of LRRK2 kinase activity.\",\n      \"method\": \"In vitro kinase assay with recombinant proteins, Co-IP from SH-SY5Y cells/mouse brain/human PBMCs, LRRK2 siRNA knockdown, kinase inhibitor treatment, overexpression studies\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution plus endogenous Co-IP plus KD with kinase-independent readout\",\n      \"pmids\": [\"26268594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"p62/SQSTM-1 physically interacts with LRRK2 as a selective autophagy receptor, mediating LRRK2 degradation through the autophagy-lysosome pathway; LRRK2 overexpression indirectly modulates p62 phosphorylation at Ser351/Ser403 and reduces the interaction of phosphorylated p62 with Keap1.\",\n      \"method\": \"Co-IP, p62 overexpression/knockdown, autophagy-lysosome pathway inhibition, phosphorylation assays\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP plus functional degradation assay, single laboratory\",\n      \"pmids\": [\"27631370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Type I LRRK2 kinase inhibitors (stabilizing closed kinase conformation) suppress Rab10/Rab12 phosphorylation and promote mitophagy; Type II inhibitors also suppress Rab phosphorylation and promote mitophagy but fail to induce dephosphorylation of N-terminal biomarker sites (e.g., Ser935), indicating these biomarker sites report on kinase open/closed conformation rather than simple catalytic activity.\",\n      \"method\": \"Phospho-Rab10/12 measurement, Ser935 phosphorylation assay, mitophagy assay, LRRK2[A2016T] resistance mutant studies\",\n      \"journal\": \"Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — systematic pharmacological dissection with resistance mutant validation and multiple orthogonal readouts\",\n      \"pmids\": [\"34515301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"R1441C mutant LRRK2 induces impaired autophagic balance at the convergent crossroads of endocytic and autophagic pathways; RNAi-knockdown of LRRK2 increases autophagic activity, indicating LRRK2 is a negative regulator of autophagy.\",\n      \"method\": \"Genomic YPet-LRRK2 reporter cell model (recombineering), R1441C mutant expression, RNAi knockdown, autophagic activity assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — novel cell model with functional autophagy readout, single laboratory\",\n      \"pmids\": [\"19770575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LRRK2 G2019S mutation promotes pathway-specific dysregulation of glutamatergic synapses in striatal spiny projection neurons, including increased AMPA receptor levels and altered organization, decreased mEPSC frequency, and changes in dendritic spine nano-architecture.\",\n      \"method\": \"R1441C and G2019S knock-in mice, biochemical synaptic fractionation, super-resolution imaging, patch-clamp electrophysiology, two-photon glutamate uncaging\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knock-in mice with multiple orthogonal imaging and electrophysiology methods\",\n      \"pmids\": [\"33006315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LRRK2 G2019S kinase activity promotes mitochondrial fission in microglia via Drp1; LPS increases LRRK2 levels and mitochondrial fission, both rescued by LRRK2 kinase inhibitor; G2019S transgenic mice show decreased mitochondrial area, elevated Drp1, and increased inflammatory markers in brain.\",\n      \"method\": \"G2019S transgenic mice, LRRK2 kinase inhibitor (GSK2578215A), mitochondrial morphology quantification, Drp1/CD68/TNF-α immunoblot\",\n      \"journal\": \"Experimental neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — transgenic model with kinase inhibitor rescue, but downstream Drp1 mechanism inferred\",\n      \"pmids\": [\"30022868\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LRRK2 is a large multidomain protein with both GTPase (Roc domain) and serine/threonine kinase activities; pathogenic PD mutations either reduce GTPase activity (R1441C/G, Y1699C) or enhance kinase activity (G2019S); LRRK2 is recruited and activated at endomembranes (particularly lysosomes under stress via the STING-CASM-GABARAP pathway and lysosomal damage), where it phosphorylates a subset of Rab GTPases (including Rab8A, Rab10, Rab12, Rab35) to regulate vesicle trafficking, lysosomal tubulation/sorting (LYTL), and autophagosome transport; PPM1H counteracts LRRK2 by dephosphorylating Rab substrates; Rab12 facilitates LRRK2 recruitment to damaged lysosomes; LRRK2 dimerization is required for kinase activity; it also regulates CMA, neuronal PKA signaling via PKARIIβ, microglial motility via FAK phosphorylation, and tau phosphorylation as a scaffold for cdk5.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract discoveries only from KEEP papers.\n\n**Papers to EXCLUDE:**\n- Additional paper [1] (Jostins et al., PMID:23128233) — GWAS association only, no mechanistic finding about LRRK2\n- Additional paper [3] (Barrett et al., PMID:18587394) — GWAS, no LRRK2 mechanism\n- Additional paper [4] (Franke et al., PMID:21102463) — GWAS, no LRRK2 mechanism\n- Additional paper [5] (Simón-Sánchez et al., PMID:19915575) — GWAS, no LRRK2 mechanism\n- Additional paper [6] (Nalls et al., PMID:25064009) — GWAS, no LRRK2 mechanism\n- Additional paper [7] (Strausberg et al., PMID:12477932) — cDNA sequencing project, not LRRK2-specific\n- Additional paper [8] (Dias et al., PMID:24252804) — review of oxidative stress in PD, no direct LRRK2 mechanism\n- Additional paper [10] (Satake et al., PMID:19915576) — GWAS, no LRRK2 mechanism\n- Additional paper [11] (Hein et al., PMID:26496610) — global interactome, not LRRK2-specific\n- Additional paper [14] (Ota et al., PMID:14702039) — cDNA sequencing, not LRRK2-specific\n- Additional paper [15] (Nalls et al., PMID:21292315) — GWAS meta-analysis, no LRRK2 mechanism\n- Additional paper [16] (Gaudet et al., PMID:21873635) — GO annotation methods, not LRRK2-specific\n- Additional paper [17] (Hamza et al., PMID:20711177) — HLA GWAS, no LRRK2 mechanism\n- Additional paper [20] (Gonzales et al., PMID:19056867) — urinary exosome proteomics, not LRRK2-specific\n- Additional paper [23] (Zhang et al., PMID:20018961) — leprosy GWAS, no LRRK2 mechanism\n- Additional paper [28] (Lin et al., PMID:26751287) — LINK-A lncRNA paper; LRRK2 mentioned as a kinase acting on HIF1α but this is about the lncRNA LINK-A in breast cancer, not about canonical LRRK2 biology in PD context — **EXCLUDE (alt-locus/context collision)**\n- Corpus paper [16] (PMID:19847307) — metabolomics/biomarker study, no direct mechanism\n- Corpus paper [19] (PMID:29309488) — clinical progression study, no mechanism\n- Corpus paper [39] (PMID:26177462) — sleep disorders clinical study, no mechanism\n- Corpus paper [40] (PMID:25650144) — cognitive profile clinical study, no mechanism\n- Corpus paper [41] (PMID:27220776) — inflammatory biomarker study, no mechanism\n- Corpus paper [60] (PMID:30761591) — urate biomarker study, no mechanism\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"LRRK2 (dardarin) was identified as a novel gene containing missense mutations segregating with PARK8-linked Parkinson's disease, establishing it as the causal gene for this familial PD locus.\",\n      \"method\": \"Positional cloning and candidate gene sequencing in five PD families\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original gene discovery, independently replicated by a concurrent study\",\n      \"pmids\": [\"15541308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LRRK2 encodes a large multifunctional protein belonging to the ROCO family, containing a MAPKKK-class protein kinase domain and a Ras-of-complex (Roc) GTPase domain, with six disease-segregating mutations identified including missense and splice-site variants; post-mortem analysis revealed strikingly diverse neuropathologies (Lewy body PD, diffuse Lewy body disease, nigral degeneration, PSP-like pathology) among mutation carriers.\",\n      \"method\": \"High-resolution recombination mapping, candidate gene sequencing, post-mortem neuropathology in 46 families\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original domain architecture characterization with genetic and pathological validation\",\n      \"pmids\": [\"15541309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PD-associated LRRK2 mutations (G2019S and R1441C) increase kinase activity in vitro, as measured by autophosphorylation and phosphorylation of a generic substrate, without altering protein levels or localization, supporting a gain-of-function mechanism.\",\n      \"method\": \"In vitro kinase assays with full-length recombinant LRRK2; subcellular fractionation showing mitochondrial outer membrane association\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay, independently replicated across multiple labs\",\n      \"pmids\": [\"16269541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Kinase activity is required for the toxic effects of mutant LRRK2: a kinase-dead version of LRRK2 blocks inclusion body formation and strongly delays neuronal cell death caused by pathogenic mutations; LRRK2 protein is expressed in human midbrain neurons and C-terminal epitopes are found in some Lewy bodies.\",\n      \"method\": \"Kinase-dead mutagenesis; neuronal cell death assays; immunocytochemistry in human brain tissue\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — active-site mutagenesis with cellular phenotypic readout, replicated\",\n      \"pmids\": [\"16750377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LRRK2 kinase activity is regulated by GTP via the intrinsic GTPase Roc domain; reducing kinase activity of mutant LRRK2 correspondingly reduces neuronal toxicity, establishing that both kinase and GTPase activities are required for neurotoxicity.\",\n      \"method\": \"GTP-binding assays; kinase-dead and GTPase-dead mutagenesis; neuronal toxicity assays\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted enzymatic assays with mutagenesis and functional toxicity readout\",\n      \"pmids\": [\"16980962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PD-associated LRRK2 mutations display disinhibited kinase activity and induce progressive reduction in neurite length and branching in primary neurons and in intact rodent CNS; LRRK2 deficiency leads to increased neurite length and branching; mutant LRRK2 neurons harbor phospho-tau-positive lysosomal inclusions and undergo apoptosis.\",\n      \"method\": \"Primary neuronal cultures; in vivo rodent CNS expression; kinase activity assays; immunofluorescence\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss- and gain-of-function with defined cellular phenotype, replicated\",\n      \"pmids\": [\"17114044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Seven of ten familial LRRK2 mutations result in increased kinase activity; LRRK2 kinase activity requires GTPase activity, whereas GTPase activity functions independently of kinase activity; both activities are required for neurotoxicity and potentiation of peroxide-induced cell death.\",\n      \"method\": \"In vitro kinase assays; GTPase activity assays; mutagenesis of conserved residues; neuronal toxicity assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted enzymatic assays with systematic mutagenesis, replicated\",\n      \"pmids\": [\"17200152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Purified brain LRRK2 possesses both kinase and GTPase activity (GTP binding and hydrolysis); PD mutations R1441C/G in the GTPase domain cause reduced GTP hydrolysis activity; brain LRRK2 is associated with elevated kinase activity compared to lung or cell-culture LRRK2.\",\n      \"method\": \"Purification of epitope-tagged LRRK2 from transgenic mouse brain; GTP binding and hydrolysis assays; kinase assays\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical assay with purified protein from physiological source\",\n      \"pmids\": [\"17623048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"C. elegans LRK-1 (LRRK2 ortholog) is localized in the Golgi apparatus and is required for polarized sorting of synaptic vesicle (SV) proteins to axons by excluding SV proteins from the dendrite-specific AP-1/UNC-101 transport machinery; loss of lrk-1 results in SV proteins localizing to both presynaptic and dendritic endings.\",\n      \"method\": \"C. elegans genetics; deletion mutants; live imaging; epistasis with AP-1 mu1 adaptor UNC-101 and kinesin UNC-104\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in model organism with defined subcellular localization and transport phenotype\",\n      \"pmids\": [\"17346966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Expression of wild-type or G2019S-LRRK2 in Drosophila causes retinal degeneration and adult-onset selective loss of dopaminergic neurons with locomotor dysfunction; G2019S causes more severe parkinsonism-like phenotype than equivalent wild-type LRRK2; L-DOPA improves locomotor impairment but does not prevent dopaminergic neuron loss.\",\n      \"method\": \"GAL4/UAS transgenic Drosophila; dopaminergic neuron counting; locomotor assays; pharmacological rescue\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function in vivo model with multiple phenotypic readouts\",\n      \"pmids\": [\"18258746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Loss of LRRK (Drosophila LRRK2 ortholog) causes severely impaired locomotor activity and degeneration/shrinkage of dopaminergic neurons (reduced tyrosine hydroxylase immunostaining), demonstrating that LRRK2 is critical for dopaminergic neuron integrity in vivo.\",\n      \"method\": \"Drosophila loss-of-function mutants; locomotor assays; tyrosine hydroxylase immunostaining\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined neuronal phenotype in vivo\",\n      \"pmids\": [\"17498648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LRRK2 kinase activity resides with dimeric LRRK2 rather than monomeric or high-molecular-weight oligomeric forms; disruption of GTPase or kinase activity enhances oligomer formation and prevents dimer formation; pathogenic mutations that increase kinase activity significantly increase the proportion of dimer structures; kinase inhibition by staurosporine ablates LRRK2 dimers.\",\n      \"method\": \"Size-exclusion chromatography/fractionation; kinase activity assays of separated fractions; kinase inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical fractionation with direct kinase activity measurement\",\n      \"pmids\": [\"19826009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LRRK2 binds to MAP kinase kinases MKK3, MKK6, and MKK7, and also binds to JNK-interacting proteins JIP1, JIP2, JIP3, and JIP4; LRRK2 association correlates with increased total JIP1, JIP3, JIP4, oligomeric JIP and ubiquitinated JIP levels, implicating LRRK2 in regulation of the stress kinase cascade.\",\n      \"method\": \"Co-immunoprecipitation; immunoblot analysis of JIP levels\",\n      \"journal\": \"Neuro-degenerative diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP binding data, single lab, no direct kinase assay of the interaction\",\n      \"pmids\": [\"20173330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ArfGAP1 is the first identified GTPase activating protein (GAP) for LRRK2; ArfGAP1 binds LRRK2 predominantly via the WD40 and kinase domains, increases LRRK2 GTPase activity, and regulates LRRK2 toxicity in vitro and in Drosophila; reciprocally, LRRK2 phosphorylates ArfGAP1 and inhibits its GAP activity, while ArfGAP1 reduces LRRK2 autophosphorylation and kinase activity.\",\n      \"method\": \"Co-IP; in vitro GTPase activity assays; in vitro kinase assays; Drosophila toxicity assays; shRNA knockdown\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical assays plus in vivo Drosophila validation\",\n      \"pmids\": [\"22423108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LRRK2 is degraded in lysosomes by chaperone-mediated autophagy (CMA); the pathogenic G2019S mutant is poorly degraded by CMA; both wild-type and pathogenic mutant LRRK2 interfere with the CMA translocation complex in the presence of other CMA substrates, resulting in defective CMA and self-perpetuating inhibition; this was observed in neuronal cultures, LRRK2 transgenic mouse brain, iPSC-derived dopaminergic neurons, and PD patient brains.\",\n      \"method\": \"Lysosomal binding assays; CMA flux measurements; LRRK2 transgenic mice; iPSC-derived DA neurons; human PD brain tissue analysis\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal models and methods, replicated in human tissue\",\n      \"pmids\": [\"23455607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RAB7L1 (encoded at the PARK16 locus) interacts with LRRK2 and modifies intraneuronal protein sorting; deficiency of RAB7L1 in rodent neurons or its Drosophila ortholog recapitulates degeneration seen with familial LRRK2 mutations; RAB7L1 overexpression rescues LRRK2 mutant phenotypes; PD-associated defects in RAB7L1 or LRRK2 lead to endolysosomal and Golgi sorting defects and deficiency of the VPS35 retromer component.\",\n      \"method\": \"Genetic epistasis in Drosophila and rodent neurons; Co-IP; retromer complex analysis; endolysosomal sorting assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis across two model organisms plus biochemical validation\",\n      \"pmids\": [\"23395371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LRRK2 negatively regulates PKA activity in striatal projection neurons (SPNs) by interacting with PKA regulatory subunit IIβ (PKARIIβ); loss of LRRK2 promotes synaptic translocation of PKA and increases PKA-mediated phosphorylation of cofilin and GluR1, causing abnormal synaptogenesis; the R1441C mutation impairs LRRK2-PKARIIβ interaction, inducing excessive PKA activity.\",\n      \"method\": \"Co-IP of LRRK2 with PKARIIβ; PKA activity assays; phosphorylation of cofilin and GluR1 in Lrrk2-/- and R1441C mice; synaptic translocation imaging\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus functional PKA activity measurements in KO and knock-in mice\",\n      \"pmids\": [\"24464040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRRK2 binds to focal adhesion kinase (FAK) and phosphorylates its Thr-X-Arg/Lys (TXR/K) motifs, attenuating FAK activity (decreased pY397 phosphorylation); G2019S-LRRK2 decreases pY397-FAK levels in brain, microglia, and HEK cells and retards ADP-induced microglial motility; LRRK2 kinase inhibition restores pY397 levels and rescues microglial motility.\",\n      \"method\": \"Co-IP of LRRK2 with FAK; in vitro kinase assays; phosphorylation assays; live-cell motility assays with G2019S transgenic microglia; LRRK2 kinase inhibitor rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Co-IP plus direct kinase assay plus functional motility rescue in transgenic cells\",\n      \"pmids\": [\"26365310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRRK2 kinase inhibition (PF-06447475) is well tolerated in rats and provides neuroprotection against α-synuclein-induced dopaminergic neurodegeneration; G2019S-LRRK2 exacerbates dopaminergic neurodegeneration and inflammation in response to α-synuclein overexpression, and both are mitigated by LRRK2 kinase inhibition.\",\n      \"method\": \"AAV-mediated α-synuclein overexpression in rat substantia nigra; LRRK2 kinase inhibitor treatment; stereological dopaminergic neuron counting; inflammatory marker assessment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological intervention with defined neuronal phenotype in vivo\",\n      \"pmids\": [\"26078453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRRK2 facilitates tau phosphorylation as a scaffold protein rather than as a direct tau kinase; LRRK2 binds tau 140-200-fold more strongly than cdk5 but has 250-480-fold lower specific activity than cdk5 on tau; cdk5 and tau co-immunoprecipitate with endogenous LRRK2; LRRK2 knockdown reduces tau phosphorylation at Ser396/Ser404 without affecting kinase inhibitor-sensitive sites.\",\n      \"method\": \"In vitro kinase assays comparing LRRK2 and cdk5; binding affinity measurements; Co-IP of endogenous LRRK2 with tau and cdk5 in SH-SY5Y cells and mouse brain; LRRK2 siRNA knockdown\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay, binding measurements, endogenous Co-IP, and siRNA knockdown\",\n      \"pmids\": [\"26268594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Phosphoproteomics identified a subset of Rab GTPases (Rab3A/B/C/D, Rab5A/B, Rab8A/B, Rab10, Rab12, Rab29, Rab35, Rab43) as bona fide physiological LRRK2 substrates; LRRK2 directly phosphorylates a conserved Thr/Ser residue in the switch-II domain in vivo and in vitro; pathogenic LRRK2 variants increase Rab phosphorylation; phosphorylation strongly decreases Rab affinity to GDP dissociation inhibitors (GDIs).\",\n      \"method\": \"Quantitative phosphoproteomics; genetics (KO cells); pharmacology (LRRK2 inhibitors); in vitro kinase assays; GDI binding assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — unbiased phosphoproteomics with genetic and pharmacological validation, in vitro confirmation; highly cited foundational study\",\n      \"pmids\": [\"26824392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LRRK2 negatively regulates α-synuclein clearance by microglia; LRRK2-KO microglia take up and clear α-synuclein more effectively than WT, associated with increased Rab5-positive early endosomes and enhanced Rab5-dynamin 1 interaction, indicating LRRK2 negatively regulates endocytosis.\",\n      \"method\": \"LRRK2-KO mouse microglia; α-synuclein uptake assays; Rab5/Rab7/Rab11 immunostaining; Rab5-dynamin 1 Co-IP\",\n      \"journal\": \"BMC neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — KO phenotype with endosomal marker characterization, single lab\",\n      \"pmids\": [\"27903237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LRRK2 interacts with p62/SQSTM-1, a selective autophagic receptor; p62 overexpression leads to robust degradation of LRRK2 through the autophagy-lysosome pathway; LRRK2 indirectly regulates Ser351 and Ser403 phosphorylation of p62 and reduces p62-Keap1 interaction.\",\n      \"method\": \"Co-IP of LRRK2 with p62; autophagy flux assays; phosphorylation analysis of p62\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP with functional degradation assay, single lab\",\n      \"pmids\": [\"27631370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The structural interface between LRRK2 and 14-3-3 proteins was characterized: phosphorylation of multiple LRRK2 sites (including Ser910/Ser935) enables multivalent 14-3-3 binding; PD-relevant mutations impair this interaction, which is connected to enhanced kinase activity, LRRK2 inclusion body formation, and reduced neurite length.\",\n      \"method\": \"Biochemical binding assays; crystal structures of 14-3-3 bound to LRRK2 phosphopeptides\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus biochemical validation\",\n      \"pmids\": [\"28202711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LRRK2 kinase activity promotes mitochondrial fission in microglia via Drp1; LPS treatment increases LRRK2 protein levels and mitochondrial fission in microglia; G2019S-LRRK2 transgenic mice show decreased mitochondrial area and reduced microglial processes; LRRK2 kinase inhibition (GSK2578215A) rescues these phenotypes and reduces CD68, Drp1, and TNF-α levels.\",\n      \"method\": \"G2019S transgenic mice; primary microglia; LRRK2 kinase inhibitor treatment; mitochondrial morphology analysis; Drp1 and inflammatory marker quantification\",\n      \"journal\": \"Experimental neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — kinase inhibitor rescue in transgenic and primary cells with defined mechanistic marker\",\n      \"pmids\": [\"30022868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PPM1H phosphatase acts as a key counterbalance to LRRK2 signaling by selectively dephosphorylating LRRK2-phosphorylated Rab proteins; PPM1H knockout increases endogenous Rab phosphorylation; PPM1H directly and efficiently dephosphorylates Rab8A in biochemical studies; a substrate-trapping PPM1H mutant (Asp288Ala) binds with high affinity to LRRK2-phosphorylated Rabs; PPM1H is localized to the Golgi and its knockdown suppresses primary cilia formation similarly to pathogenic LRRK2.\",\n      \"method\": \"siRNA screen of all human phosphatases; PPM1H KO cells; in vitro dephosphorylation assays; substrate-trapping mutant; Golgi localization imaging; cilia formation assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — unbiased siRNA screen, in vitro biochemical validation, multiple orthogonal assays\",\n      \"pmids\": [\"31663853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of the WD40 domain of human LRRK2 at 2.6-Å resolution reveals a seven-bladed WD40 fold that forms dimers in crystal and in solution; PD-associated and structure-based mutations in the WD40 domain (including G2385R) mainly compromise dimer formation; WD40 dimerization-defective mutants including G2385R show enhanced kinase activity as measured by Rab10 phosphorylation.\",\n      \"method\": \"X-ray crystallography; solution measurements of dimerization; phospho-Rab10 kinase activity assays of WD40 mutants\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional mutagenesis validation\",\n      \"pmids\": [\"30635421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LRRK2 is recruited to lysosomes after lysosome membrane rupture (LLOME exposure) and mediates lysosomal tubulation/sorting (LYTL); LRRK2 recruits motor adaptor JIP4 to lysosomes in a kinase-dependent manner via phosphorylation of RAB35 and RAB10; JIP4 promotes formation of LAMP1-negative tubules that release membranous vesicles from lysosomes.\",\n      \"method\": \"Unbiased proteomic screen (APEX proximity labeling); super-resolution live-cell imaging; FIB-SEM; LRRK2 kinase inhibitors; RAB phosphorylation assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — unbiased proteomics, super-resolution imaging, FIB-SEM structural validation, kinase-dependent rescue\",\n      \"pmids\": [\"33177079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Lysosomal stress agents (lysosomotropic drugs, nigericin, monensin, chloroquine, LLOMe) potently stimulate LRRK2-dependent Rab10 phosphorylation and promote formation of LRRK2-coated enlarged lysosomes; this upregulation occurs not by increasing LRRK2 enzymatic activity per se but by enhancing molecular proximity between LRRK2 and Rab GTPase substrates on lysosomal surfaces; the effect is downstream of Rab29-mediated LRRK2 activation.\",\n      \"method\": \"Lysosomal stress agent treatment; Rab10 phosphorylation assays; LRRK2 autophosphorylation at Ser1292; proximity measurements; Rab29 KO cells\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological and genetic perturbations with mechanistic dissection\",\n      \"pmids\": [\"32919031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LRRK2-mediated hyperphosphorylation of RAB proteins recruits SPAG9/JIP4 to autophagosomal membranes; increased JIP4 on autophagosomes induces abnormal kinesin-1 recruitment and activation, creating an unproductive tug-of-war between anterograde and retrograde motors that impairs processive autophagosome transport and maturation in axons.\",\n      \"method\": \"Live-cell imaging of autophagosome transport in neurons; G2019S-LRRK2 expression; kinase-dependent rescue; kinesin-1 and JIP4 co-localization assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — live imaging with kinase-dependent mechanistic dissection, single lab\",\n      \"pmids\": [\"34110246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Rab29 knockout does not influence basal endogenous LRRK2 activity (Rab10 and Rab12 phosphorylation) in wild-type, R1441C knock-in, or VPS35[D620N] knock-in mice or primary cells; nigericin induces the greatest increase (5-9-fold) in Rab10/Rab12 phosphorylation in a LRRK2 inhibitor-sensitive but Rab29-independent manner.\",\n      \"method\": \"Rab29 KO mice; Rab10/Rab12 phosphorylation assays in brain and fibroblasts; lysosomal stress agents; LRRK2 inhibitors\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO across multiple tissues and genotypes with pharmacological validation\",\n      \"pmids\": [\"33135724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Type I LRRK2 inhibitors (binding closed kinase conformation) and Type II inhibitors (binding open conformation) both suppress phosphorylation of Rab10 and Rab12 and promote mitophagy; Type II inhibitors fail to induce dephosphorylation of N-terminal biomarker phosphosites (Ser935), demonstrating that these biomarker sites report on kinase conformation (open vs. closed) rather than catalytic activity per se.\",\n      \"method\": \"Rab10/Rab12 phosphorylation assays; mitophagy assays; Ser935 dephosphorylation; LRRK2[A2016T] resistance mutant validation\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — systematic comparison of inhibitor classes with mechanistic dissection using resistance mutant\",\n      \"pmids\": [\"34515301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structure of the catalytic half of LRRK2 (kinase in closed conformation + GTPase domains) bound to microtubules was determined; specific residues in LRRK2's GTPase domain mediate microtubule binding; mutation of these residues disrupts microtubule binding in vitro and in cells without affecting kinase activity; LRRK1, though structurally similar, does not interact with microtubules.\",\n      \"method\": \"Cryo-EM structure determination; in vitro microtubule binding assays; mutagenesis; cell-based co-localization assays\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with mutagenesis validation in vitro and in cells\",\n      \"pmids\": [\"36510024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LRRK2 activation and Rab10 phosphorylation at lysosomes is regulated by lysosomal positioning; anterograde transport of lysosomes to the cell periphery (via ARL8B/SKIP overexpression or JIP4 knockdown) blocks LRRK2-dependent Rab10 recruitment and phosphorylation and prevents LYTL lysosomal tubulation; perinuclear lysosomal clustering (via RILP overexpression) increases LRRK2-dependent Rab10 phosphorylation; PPM1H knockdown significantly increases pRab10 and lysosomal tubulation.\",\n      \"method\": \"Directed LRRK2 localization system; ARL8B/SKIP overexpression; RILP overexpression; JIP4 KD; PPM1H KD; super-resolution imaging of pRab10 and lysosomal tubulation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal genetic perturbations with imaging readout demonstrating spatial regulation\",\n      \"pmids\": [\"36256825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Directing LRRK2 to any membrane of the endolysosomal pathway (Golgi, lysosomes, plasma membrane, recycling/early/late endosomes) via rapamycin-dependent oligomerization is sufficient to trigger local accumulation of phosphorylated RAB10, RAB12, and JIP4 recruitment, irrespective of membrane identity; endogenous Rab29 is not required for LRRK2 activation at Golgi or lysosomes.\",\n      \"method\": \"Rapamycin-dependent LRRK2 targeting to specific organelles; phospho-RAB10/RAB12 immunofluorescence; JIP4 recruitment; Rab29 KO validation\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic organelle targeting with multiple readouts and genetic controls\",\n      \"pmids\": [\"35580815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Rab12 is a novel modulator of LRRK2-dependent Rab10 phosphorylation; Rab12 is recruited to damaged lysosomes and drives local LRRK2-dependent increases in Rab10 phosphorylation at the lysosome; PD-linked variants LRRK2 R1441G and VPS35 D620N increase LRRK2 recruitment to lysosomes and elevate lysosomal pT73-Rab10 levels.\",\n      \"method\": \"siRNA screen; lysosome immunopurification; imaging of Rab12 recruitment; Rab10 phosphorylation assays; PD knock-in variants\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA screen with mechanistic follow-up using lysosome isolation and PD variants\",\n      \"pmids\": [\"37874617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"STING signaling activates LRRK2 kinase activity at lysosomes through the CASM (conjugation of ATG8 to single membranes) pathway; multiple stimuli that perturb lysosomal homeostasis converge on CASM to activate LRRK2; LRRK2 lysosome recruitment and kinase activation are highly dependent on interactions with GABARAP (an ATG8 family member) rather than other ATG8 proteins.\",\n      \"method\": \"STING agonist treatment; CASM pathway perturbation; GABARAP interaction assays; LRRK2 lysosome recruitment imaging; Rab phosphorylation as kinase activity readout\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple stimuli and pathway perturbations with specific protein interaction identified\",\n      \"pmids\": [\"39812709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Mutant LRRK2 (G2019S and R1441C) expression in cortical neurons increases whole-cell current responses to AMPA and NMDA receptor agonists, increases frequency of spontaneous miniature EPSCs, and increases excitatory synapse density; mutant neurons show enhanced vulnerability to synaptic glutamate stress; NMDA receptor antagonist memantine protects against dendrite degeneration caused by mutant LRRK2.\",\n      \"method\": \"Whole-cell voltage clamp in cultured rat cortical neurons; mEPSC recordings; immunofluorescence for PSD95/VGLUT1; pharmacological rescue with memantine\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — electrophysiology with defined synaptic phenotype and pharmacological rescue, single lab\",\n      \"pmids\": [\"24874075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRRK2 promotes accumulation of non-monomeric and high-molecular-weight Tau species and increases Tau secretion independently of LRRK2 kinase activity, possibly through impairment of Tau proteasomal degradation; LRRK2 directly interacts with Tau.\",\n      \"method\": \"Co-IP of LRRK2 with Tau; size-exclusion/native PAGE analysis of Tau species; proteasome activity assays; Tau secretion measurement\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP with functional Tau species analysis, single lab\",\n      \"pmids\": [\"26014385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The R1441C mutant form of LRRK2 (expressed from a genomic DNA YPet-LRRK2 reporter) induces impaired autophagic balance at the endocytic-autophagic crossroads; conversely, RNAi-induced knockdown of LRRK2 increases autophagic activity, demonstrating that LRRK2 acts as a negative regulator of autophagic activity.\",\n      \"method\": \"Genomic DNA reporter (STEP recombineering); autophagic flux assays; RNAi knockdown\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — gain and loss-of-function with autophagic flux readout, single lab\",\n      \"pmids\": [\"19770575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"R1441C and G2019S LRRK2 knock-in mutations increase levels and alter nanoscale organization of glutamatergic AMPA receptors at synapses of striatal projection neurons; these mutations decrease frequency of miniature EPSCs and alter dendritic spine nano-architecture, with effects exaggerated in direct pathway SPNs for R1441C.\",\n      \"method\": \"Super-resolution imaging (STORM); biochemical synaptic fractionation; miniature EPSC recordings; two-photon glutamate uncaging\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — super-resolution structural imaging plus electrophysiology in knock-in mice\",\n      \"pmids\": [\"33006315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LRRK2 mutant iPSC-derived DA neurons show increased expression of oxidative stress-response genes and α-synuclein protein, and are more sensitive to caspase-3 activation and cell death caused by hydrogen peroxide, MG-132, and 6-hydroxydopamine compared to control DA neurons.\",\n      \"method\": \"iPSC generation from G2019S-LRRK2 patients; DA neuron differentiation; transcriptomic analysis; caspase-3 activation; cell death assays\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient-derived iPSC model with multiple stress paradigms, highly cited\",\n      \"pmids\": [\"21362567\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LRRK2 is a large multidomain kinase/GTPase of the ROCO family that phosphorylates a defined subset of Rab GTPases (including Rab8A, Rab10, Rab12, Rab35) on a conserved switch-II motif residue; its kinase activity is activated by membrane recruitment to endolysosomal compartments (regulated by GABARAP/CASM signaling, Rab12, and lysosomal positioning), requires GTPase domain function, depends on a dimeric assembly state, is counterbalanced by the phosphatase PPM1H, and is regulated by 14-3-3 binding to phosphorylated N-terminal sites; pathogenic PD mutations (particularly G2019S, R1441C/G, Y1699C) increase kinase activity or impair GTPase activity, leading to hyperphosphorylation of Rab substrates that disrupts vesicular trafficking, lysosomal tubulation/sorting (LYTL), autophagosome transport, synaptogenesis, microglial motility, and chaperone-mediated autophagy.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LRRK2 is a large multidomain enzyme with both GTPase (Roc domain) and serine/threonine kinase activities that functions as a central regulator of endomembrane trafficking, lysosomal homeostasis, and autophagy, with causative mutations underlying PARK8-linked autosomal-dominant Parkinson's disease [PMID:15541308]. Kinase activity requires dimerization and an intact GTPase domain, while PD-associated mutations either reduce GTP hydrolysis (R1441C/G) or enhance kinase output (G2019S); LRRK2 is recruited to damaged or stressed lysosomes through a CASM–GABARAP-dependent pathway facilitated by Rab12, where it phosphorylates Rab GTPases (Rab8A, Rab10, Rab12, Rab35) to drive JIP4-mediated lysosomal tubulation and sorting (LYTL) and to regulate autophagosome transport [PMID:17623048, PMID:19826009, PMID:33177079, PMID:34110246, PMID:37874617, PMID:39812709]. Beyond endomembrane control, LRRK2 scaffolds cdk5-dependent tau phosphorylation, negatively regulates PKA signaling through interaction with PKARIIβ in striatal neurons, modulates chaperone-mediated autophagy of α-synuclein, and attenuates microglial motility by phosphorylating FAK [PMID:26268594, PMID:24464040, PMID:23455607, PMID:26365310]. PPM1H is the counteracting phosphatase that dephosphorylates LRRK2-phosphorylated Rab substrates, and 14-3-3 proteins bind phosphorylated LRRK2 to restrain its kinase activity and prevent pathological aggregation [PMID:31663853, PMID:28202711].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of LRRK2 as the PARK8 gene established that mutations in this novel multidomain protein directly cause familial Parkinson's disease, focusing all subsequent mechanistic inquiry.\",\n      \"evidence\": \"Positional cloning and linkage analysis across five PD families\",\n      \"pmids\": [\"15541308\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymatic activities of the protein were unknown\", \"Cellular substrates unidentified\", \"Normal physiological function undetermined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstration that LRRK2 possesses intrinsic GTPase activity and that PD mutations (R1441C/G) impair GTP hydrolysis while kinase activity requires the GTPase domain resolved the functional hierarchy between LRRK2's two enzymatic domains.\",\n      \"evidence\": \"GTP binding/hydrolysis assays with purified LRRK2 from transgenic mouse brain and domain truncation mutants\",\n      \"pmids\": [\"17623048\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase substrates remained unknown\", \"Structural basis for GTPase–kinase coupling unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Studies in C. elegans and Drosophila orthologs established that LRRK2 functions in vivo in polarized vesicle sorting (at the Golgi) and is required for dopaminergic neuron survival, linking its molecular activity to neuronal biology.\",\n      \"evidence\": \"C. elegans lrk-1 deletion mutants with genetic epistasis; Drosophila LRRK loss-of-function with DA neuron quantification\",\n      \"pmids\": [\"17346966\", \"17498648\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether mammalian LRRK2 has equivalent Golgi sorting function was untested\", \"Substrates mediating vesicle sorting unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showing that LRRK2 kinase activity resides exclusively in the dimeric form, and that PD mutations favoring dimers increase kinase output, established dimerization as a key activation mechanism and potential therapeutic target.\",\n      \"evidence\": \"Size-exclusion chromatography separation of oligomeric states with in vitro kinase assays and kinase inhibitor treatment\",\n      \"pmids\": [\"19826009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of dimerization interface unknown at the time\", \"Whether dimerization is regulated in cells was unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of ArfGAP1 as the first GAP for LRRK2's GTPase domain, showing reciprocal regulation (ArfGAP1 stimulates GTP hydrolysis while LRRK2 phosphorylates and inhibits ArfGAP1), revealed a feedback loop controlling LRRK2 enzymatic output.\",\n      \"evidence\": \"Co-IP, in vitro GTPase and kinase assays, Drosophila toxicity model, shRNA knockdown\",\n      \"pmids\": [\"22423108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ArfGAP1 is the physiologically dominant GAP in neurons was unclear\", \"Downstream consequences for Arf-dependent trafficking not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that LRRK2 is degraded by chaperone-mediated autophagy and that both WT and mutant LRRK2 disrupt CMA translocation complex organization — impairing α-synuclein clearance — provided a direct mechanistic link between LRRK2 dysfunction and α-synuclein accumulation in PD.\",\n      \"evidence\": \"Lysosomal binding/uptake assays, CMA substrate competition, iPSC-derived DA neurons, LRRK2 transgenic mice, and PD patient brain\",\n      \"pmids\": [\"23455607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the CMA translocation complex component disrupted by LRRK2 was not defined\", \"Whether CMA blockade is kinase-dependent was not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that LRRK2 negatively regulates PKA signaling in striatal neurons by binding PKARIIβ, and that PD mutations disrupt this interaction causing excessive PKA activity and abnormal synaptogenesis, established a kinase-independent scaffolding function with direct synaptic consequences.\",\n      \"evidence\": \"Reciprocal Co-IP, Lrrk2 KO and R1441C knock-in mice, confocal imaging, electrophysiology\",\n      \"pmids\": [\"24464040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PKA dysregulation contributes to DA neuron loss was untested\", \"Whether the G2019S mutation similarly disrupts PKARIIβ binding was not shown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of LRRK2 as a scaffold for cdk5-dependent tau phosphorylation (binding tau with high affinity while having minimal direct kinase activity toward tau) and of FAK as a direct kinase substrate controlling microglial motility expanded the substrate repertoire beyond Rab GTPases.\",\n      \"evidence\": \"In vitro kinase assays with recombinant proteins, endogenous Co-IP from brain, LRRK2 siRNA, kinase inhibitor rescue of microglial motility\",\n      \"pmids\": [\"26268594\", \"26365310\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of tau scaffolding to tauopathy progression was not established\", \"FAK phosphorylation site(s) not precisely mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Structural and biochemical characterization of 14-3-3 binding to phosphorylated LRRK2 showed that PD mutations disrupt this interaction, connecting loss of 14-3-3 restraint to enhanced kinase activity, ubiquitination, and neurite shortening.\",\n      \"evidence\": \"Crystal structures of 14-3-3/LRRK2 phosphopeptide complexes, biochemical binding assays\",\n      \"pmids\": [\"28202711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which kinase phosphorylates LRRK2 at 14-3-3 binding sites in vivo was not fully resolved\", \"Whether restoring 14-3-3 binding rescues PD phenotypes was untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Crystal structure of the WD40 domain dimer and identification of PPM1H as the Rab-counteracting phosphatase resolved two key structural and regulatory questions: how LRRK2 dimerizes (WD40-mediated) and how Rab phosphorylation is reversed.\",\n      \"evidence\": \"X-ray crystallography of WD40 domain at 2.6 Å with pRab10 kinase assays; unbiased phosphatase siRNA screen with in vitro reconstitution and PPM1H KO cells\",\n      \"pmids\": [\"30635421\", \"31663853\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PPM1H activity is itself regulated by LRRK2 was unknown\", \"Full-length LRRK2 dimer structure not yet available\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Multiple studies converged to show that LRRK2 is recruited to stressed/damaged lysosomes where proximity to Rab substrates (not increased intrinsic kinase activity) drives local Rab phosphorylation, JIP4 recruitment, and a novel lysosomal tubulation/sorting pathway (LYTL), establishing the lysosome as the primary site of LRRK2 signaling.\",\n      \"evidence\": \"Unbiased proteomics, super-resolution and FIB-SEM imaging, lysosomotropic drug treatments, proximity ligation, Rab29 KO mice\",\n      \"pmids\": [\"33177079\", \"32919031\", \"33135724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological triggers of lysosomal LRRK2 activation in neurons in vivo were unknown\", \"Cargo sorted by LYTL tubules not identified\", \"Whether Rab29 has any role at all was debated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that hyperactive G2019S-LRRK2 disrupts processive axonal autophagosome transport by recruiting JIP4 to autophagosomes (causing a kinesin-1/dynein tug-of-war) extended the LRRK2–JIP4–Rab axis from lysosomes to autophagic vesicles and provided a mechanism for impaired autophagosome maturation in PD.\",\n      \"evidence\": \"Live-cell imaging of axonal autophagosome transport, JIP4 knockdown/overexpression, LRRK2 kinase inhibitor rescue\",\n      \"pmids\": [\"34110246\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this transport defect occurs in human DA neurons was not shown\", \"Specific Rab mediating JIP4 recruitment to autophagosomes not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Cryo-EM structure of LRRK2's catalytic half on microtubules revealed that the GTPase domain mediates microtubule association independently of kinase activity, while forced membrane targeting showed that endomembrane recruitment alone is sufficient for LRRK2 activation regardless of the specific compartment or Rab29.\",\n      \"evidence\": \"Cryo-EM at near-atomic resolution with mutagenesis; rapamycin-inducible organelle targeting with pRab readouts in Rab29 KO cells\",\n      \"pmids\": [\"36510024\", \"35580815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of microtubule binding in vivo unclear\", \"Whether microtubule binding and membrane recruitment are competitive was not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Spatial regulation of LRRK2 signaling was established: perinuclear lysosomes support pRab10 accumulation and LYTL, while anterograde lysosome transport suppresses LRRK2 output, indicating that subcellular positioning of lysosomes tunes LRRK2 pathway activity.\",\n      \"evidence\": \"Directed lysosomal transport manipulation (ARL8B/SKIP/RILP), super-resolution pRab10/pRab12 imaging, PPM1H knockdown\",\n      \"pmids\": [\"36256825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether perinuclear clustering is altered in PD patient cells was untested\", \"How PPM1H accesses perinuclear lysosomes specifically was not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of Rab12 as a key upstream regulator that is recruited to damaged lysosomes to locally activate LRRK2 (driving Rab10 phosphorylation) resolved how LRRK2 senses lysosomal damage and connected PD-linked VPS35 D620N to the same pathway.\",\n      \"evidence\": \"Targeted siRNA screen, lysosome immunopurification, R1441G and VPS35 D620N knock-in models\",\n      \"pmids\": [\"37874617\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Rab12 is the sole lysosomal damage sensor for LRRK2 was unknown\", \"How Rab12 itself detects membrane damage was not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery that STING activation triggers LRRK2 lysosomal recruitment via the CASM (ATG8 conjugation to single membranes) pathway, specifically requiring GABARAP, unified multiple lysosome-perturbing stimuli under a single upstream mechanism and linked innate immune signaling to LRRK2 activation.\",\n      \"evidence\": \"STING agonist treatment, CASM pathway perturbation, GABARAP interaction studies, LRRK2 kinase activity assays\",\n      \"pmids\": [\"39812709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GABARAP directly binds LRRK2 or acts indirectly was not fully resolved\", \"Relevance of STING–LRRK2 axis to neuroinflammation in PD brain untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the full-length structure of active dimeric LRRK2 at endomembranes, the identity of cargoes sorted by LYTL tubules, whether microtubule binding and membrane recruitment represent competing or sequential LRRK2 states, and how LRRK2 pathway hyperactivation leads specifically to dopaminergic neuron vulnerability in PD.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length active LRRK2 dimer structure on membranes not available\", \"LYTL cargo identity unknown\", \"Basis for DA neuron selective vulnerability not mechanistically defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 5, 7, 10, 13, 14, 15, 24]},\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [1, 7]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [9, 24]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 11, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [8, 15, 16, 20, 21, 22, 23]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [2, 21]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [21]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [11, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [2, 11, 15, 20, 22]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [8, 18, 25, 26, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 9, 14, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 3, 4, 28, 29]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [15, 20, 22, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RAB10\",\n      \"RAB12\",\n      \"RAB35\",\n      \"JIP4\",\n      \"PRKAR2B\",\n      \"ARFGAP1\",\n      \"YWHAZ\",\n      \"FAK\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"LRRK2 is a large multidomain ROCO-family enzyme that integrates serine/threonine kinase and GTPase activities to regulate endolysosomal membrane trafficking, autophagy, and neuronal integrity. Its principal physiological substrates are a subset of Rab GTPases (Rab8A, Rab10, Rab12, Rab35 and others), which LRRK2 phosphorylates on a conserved switch-II residue in a reaction that requires GTP-bound Roc domain activity, dimeric assembly, and membrane recruitment to endolysosomal compartments—a process governed by the CASM/GABARAP pathway, lysosomal positioning, and counterbalanced by the phosphatase PPM1H [PMID:26824392, PMID:33177079, PMID:31663853, PMID:36256825, PMID:39812709]. Phosphorylated Rabs recruit the motor adaptor JIP4, driving lysosomal tubulation/sorting (LYTL) and modulating autophagosome transport; pathogenic Parkinson disease mutations (G2019S, R1441C/G, Y1699C) increase kinase output or impair GTPase hydrolysis, leading to Rab hyperphosphorylation that disrupts vesicular trafficking, synaptic organization, microglial motility, and chaperone-mediated autophagy [PMID:33177079, PMID:34110246, PMID:23455607, PMID:26365310, PMID:33006315]. Mutations in LRRK2 are the most common genetic cause of familial Parkinson disease (PARK8 locus), with gain-of-function kinase activity required for neurotoxicity and amenable to pharmacological inhibition [PMID:15541308, PMID:16750377, PMID:26078453].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of LRRK2 as the PARK8 gene established the first high-confidence causal locus for autosomal-dominant Parkinson disease and revealed its unique multidomain architecture containing both kinase (MAPKKK-class) and Roc GTPase domains.\",\n      \"evidence\": \"Positional cloning, candidate gene sequencing, and post-mortem neuropathology across dozens of PD families\",\n      \"pmids\": [\"15541308\", \"15541309\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No enzymatic characterization yet performed\", \"Mechanism linking mutations to neurodegeneration unknown\", \"Physiological substrates unidentified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrating that PD mutations increase kinase activity and that kinase-dead versions abolish toxicity established a gain-of-function kinase mechanism as the driver of LRRK2-mediated neurodegeneration, while GTPase activity was shown to regulate kinase output.\",\n      \"evidence\": \"In vitro kinase assays with recombinant LRRK2; kinase-dead and GTPase-dead mutagenesis; neuronal toxicity and neurite length assays in primary neurons and rodent CNS\",\n      \"pmids\": [\"16269541\", \"16750377\", \"16980962\", \"17114044\", \"17200152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological kinase substrates still unknown\", \"Mechanism of GTPase-to-kinase signal transduction unclear\", \"No structural information on any domain\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Characterization of LRRK2 in C. elegans and Drosophila revealed conserved roles in polarized vesicle sorting and dopaminergic neuron maintenance, placing LRRK2 squarely in the membrane trafficking pathway.\",\n      \"evidence\": \"C. elegans lrk-1 mutants with synaptic vesicle mis-sorting; Drosophila LRRK loss-of-function with DA neuron degeneration; Drosophila G2019S overexpression with dose-dependent DA neuron loss\",\n      \"pmids\": [\"17346966\", \"17498648\", \"18258746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mammalian trafficking substrates not identified\", \"Mechanism of vesicle sorting regulation unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that kinase activity resides with the LRRK2 dimer and that R1441C impairs autophagic balance linked the quaternary structure of LRRK2 to its catalytic regulation and positioned it as a negative regulator of autophagy.\",\n      \"evidence\": \"Size-exclusion chromatography with kinase activity measurement of separated fractions; autophagic flux assays with LRRK2 knockdown and R1441C expression\",\n      \"pmids\": [\"19826009\", \"19770575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of dimerization unknown\", \"Autophagic substrates or effectors not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Two parallel discoveries—that LRRK2 is degraded by and inhibits chaperone-mediated autophagy (CMA), and that RAB7L1 genetically interacts with LRRK2 in endolysosomal sorting—converged to define the endolysosomal system as the principal cellular context for LRRK2 function and dysfunction.\",\n      \"evidence\": \"CMA lysosomal binding assays in iPSC-derived DA neurons, transgenic mice, and PD brain; genetic epistasis of Rab7L1 and LRRK2 in Drosophila and rodent neurons with retromer analysis\",\n      \"pmids\": [\"23455607\", \"23395371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct LRRK2-Rab interaction mechanism unknown\", \"Retromer connection not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"LRRK2 was found to scaffold PKA signaling in striatal neurons, with loss of function or the R1441C mutation causing excessive PKA-mediated phosphorylation of synaptic targets (cofilin, GluR1) and abnormal synaptogenesis, revealing a kinase-independent scaffolding role at synapses.\",\n      \"evidence\": \"Co-IP of LRRK2 with PKARIIβ; PKA activity assays in Lrrk2-KO and R1441C knock-in mice; synapse imaging\",\n      \"pmids\": [\"24464040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PKA scaffolding is independent of or linked to Rab phosphorylation unclear\", \"Synaptic phenotype not tested with kinase inhibitors\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Unbiased phosphoproteomics identified a defined subset of Rab GTPases as bona fide LRRK2 substrates phosphorylated on a conserved switch-II residue, fundamentally redefining the LRRK2 signaling pathway and providing the first pharmacodynamic biomarkers for kinase activity.\",\n      \"evidence\": \"Quantitative phosphoproteomics in KO cells and with LRRK2 inhibitors; in vitro kinase assays; GDI binding assays showing phosphorylation impairs Rab recycling\",\n      \"pmids\": [\"26824392\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of individual Rab phosphorylation events largely uncharacterized\", \"Relative contribution of each Rab substrate to disease unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Two structural milestones—the WD40 domain crystal structure revealing a dimerization interface disrupted by PD variants, and identification of PPM1H as the opposing phosphatase for LRRK2-phosphorylated Rabs—defined the structural basis of kinase regulation and the signaling off-switch.\",\n      \"evidence\": \"X-ray crystallography of WD40 domain with mutagenesis; unbiased siRNA phosphatase screen identifying PPM1H; in vitro dephosphorylation and cilia formation assays\",\n      \"pmids\": [\"30635421\", \"31663853\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length LRRK2 structure not yet determined\", \"PPM1H regulation in disease contexts not explored\", \"PPM1H-LRRK2 interplay at lysosomes not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"LRRK2 was shown to be recruited to stressed lysosomes where it phosphorylates Rab10/Rab35 and recruits the motor adaptor JIP4 to drive lysosomal tubulation/sorting (LYTL), establishing the core effector mechanism downstream of Rab phosphorylation; separately, lysosomal positioning was found to regulate LRRK2 activation, and forced membrane recruitment to any endolysosomal compartment was sufficient to activate the pathway.\",\n      \"evidence\": \"APEX proximity proteomics; super-resolution and FIB-SEM imaging of lysosomal tubules; rapamycin-induced membrane targeting; lysosomal positioning perturbations (ARL8B/RILP); Rab29-KO mice\",\n      \"pmids\": [\"33177079\", \"32919031\", \"35580815\", \"36256825\", \"33135724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cargo sorted by LYTL tubules not defined\", \"Physiological triggers of lysosomal LRRK2 recruitment in neurons incompletely understood\", \"Rab29 dispensability conflicts with earlier overexpression data\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Cryo-EM structure of the LRRK2 catalytic half bound to microtubules revealed the GTPase domain mediates microtubule interaction independently of kinase activity, providing the first near-atomic structural framework for understanding LRRK2 filament formation on microtubules seen with pathogenic mutants and Type I kinase inhibitors.\",\n      \"evidence\": \"Cryo-EM at sub-nanometer resolution; mutagenesis of microtubule-binding residues validated in vitro and in cells\",\n      \"pmids\": [\"36510024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length dimeric LRRK2 structure with regulatory domains still lacking\", \"Functional significance of microtubule decoration in neurons debated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Rab12 was identified as a novel upstream modulator that recruits LRRK2 to damaged lysosomes and potentiates local Rab10 phosphorylation, clarifying the feed-forward amplification loop at lysosomes.\",\n      \"evidence\": \"siRNA screen; lysosome immunopurification; imaging of Rab12 recruitment; validation with LRRK2 R1441G and VPS35 D620N knock-in variants\",\n      \"pmids\": [\"37874617\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Rab12 is phosphorylated before or after LRRK2 recruitment unclear\", \"Redundancy among Rab substrates in recruitment not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The CASM (conjugation of ATG8 to single membranes) pathway, activated by STING signaling and other lysosomal perturbations, was identified as a major upstream regulator of LRRK2 lysosomal recruitment, with GABARAP specifically mediating LRRK2 membrane engagement.\",\n      \"evidence\": \"STING agonist treatment; CASM pathway perturbation; GABARAP interaction assays; Rab phosphorylation readouts\",\n      \"pmids\": [\"39812709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of LRRK2-GABARAP interaction not resolved\", \"Whether CASM-LRRK2 axis operates in neurons and microglia in vivo not demonstrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length structure of dimeric LRRK2 in active versus autoinhibited states, the identity of cargoes sorted by LYTL tubules, the relative pathogenic contributions of individual Rab substrate phosphorylation events, and whether therapeutic kinase inhibition can reverse disease-relevant phenotypes in humans without adverse effects from on-target lysosomal or pulmonary toxicity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length active/autoinhibited LRRK2 dimer structure missing\", \"LYTL tubule cargo identity unknown\", \"Therapeutic window for kinase inhibition in humans not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 3, 4, 5, 6, 7, 17, 20, 26, 27]},\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [4, 7, 13]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [16, 19]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [2, 6, 17, 20, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [14, 27, 28, 33, 34, 35, 36]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [8, 34]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [15, 34]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [32]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [27, 29, 34]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [8, 15, 20, 27, 33, 34, 35]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [14, 22, 29, 39]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [16, 20, 25, 36]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [5, 9, 10, 37, 40]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 41]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [27, 28, 33, 35]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RAB10\",\n      \"RAB12\",\n      \"RAB8A\",\n      \"RAB35\",\n      \"SPAG9\",\n      \"PPM1H\",\n      \"GABARAP\",\n      \"ARFGAP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}